[COMPANY_001] R
esearch  and Development  
KJX839  
Clinical Trial Protocol CKJX839A1US02 / [STUDY_ID_REMOVED]  
A randomi
zed, multicenter,  open -label  trial comparing  the 
effectiveness  of an "inclisiran  first"  implementation  strategy 
to usual  care on LDL cholesterol  (LDL -C) in patients  with 
atherosclerotic  cardiovascular  disease and elevated  LDL- C 
(≥70 mg/dL) despi[INVESTIGATOR_131265]  (VICTORION -INITIATE)  
Document  type:  Clinical Trial Protocol  
EUDRACT  number:  Not applicable  
Version  number:  02 (Amended Protocol)  
Clinical Trial Phase:  IIIb 
Release  date:  20-Oct- 2022 (content  final)
Property  of [COMPANY_001] 
Confidential  
May not be used,  divulged,  published,  or otherwise disclosed 
without the consent of [COMPANY_001]  
Clinical  Trial Protocol  Template Version 3.0 dated 31-Jan-2020 

[COMPANY_001]  Confidential  Page  2 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
Table  of contents  
Table  of contents  .................................................................................................................. [ADDRESS_148258] of figures  ....................................................................................................................... 6 
Glossary  of terms  ............................................................................................................... 10 
Amendment 02 .......................................................................................................................... 13 
Amendment 01 .......................................................................................................................... 13 
Protocol summary  .............................................................................................................. 15 
1 Introduction  ........................................................................................................................ 22 
1.1 Background  ............................................................................................................ 22 
1.1.1 Atherosclerotic cardiovascular  disease (ASCVD)  ................................ 22 
1.1.2 Mechanism  of RNA interference  ........................................................... 23 
1.1.3 Inclisiran  ................................................................................................ 23 
1.1.4 Nonclinical studies  ................................................................................ 24 
1.1.5 Clinical studies  ...................................................................................... 24 
1.2 Purpose  ................................................................................................................... 24 
2 Objectives,  endpoints and estimands  ................................................................................. 26 
2.1 Primary  estimands  .................................................................................................. 27 
2.2 Secondary estimands  .............................................................................................. 28 
3 Study design ....................................................................................................................... 29 
4 Rationale  ............................................................................................................................ 31 
4.1 Rationale for study design  ...................................................................................... 31 
4.1.1 Rat
ionale for choice of background therapy  ......................................... 33 
4.2 Rationale for dose/regimen  and duration of treatment ........................................... 33 
4.3 Rationale for choice of control drugs (comparator/placebo)  or combination 
drugs  ....................................................................................................................... 34 
4.4 Purpose and timing  of interim analyses/design  adaptations  ................................... 34 
4.5 Risks  and benefits  .................................................................................................. 34 
4.6 Rationale for Public Health  Emergency  mitigation  procedures  ............................. 35 
5 Study Population  ................................................................................................................ 35 
5.1 Inclusion criteria  .................................................................................................... 35 
5.2 Exclusion criteria  ................................................................................................... 36 
6 Treatment  ........................................................................................................................... 38 
6.1 Study treatment  ...................................................................................................... 38 
[COMPANY_001]  Confidential  Page  3 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
6.1.1 Investigational and control drugs  .......................................................... 38 
6.1.2 Additional study treatments  ................................................................... 38 
6.1.3 Treatment  arms/group ............................................................................ 38 
6.1.4 Treatment  duration  ................................................................................ 38 
6.2 Other  treatment(s) .................................................................................................. 38 
6.2.1 Concomitant therapy  ............................................................................. 38 
6.2.2 Prohibited medication  ............................................................................ 39 
6.3 Participant  numbering, treatment  assignment,  randomization  ............................... 39 
6.3.1 Participant  numbering ............................................................................ 39 
6.3.2 Treatment  assignment,  randomization  ................................................... 40 
6.4 Treatment  blinding  ................................................................................................. 40 
6.5 Dose  escalation  and dose modification  .................................................................. 40 
6.5.1 Dose  modifications  ................................................................................ 40 
6.5.2 Follow-up for toxicities  ......................................................................... 41 
6.6 Additional treatment  guidance  ............................................................................... 43 
6.6.1 Treatment  compliance  ........................................................................... 43 
6.7 Preparation  and dispensation .................................................................................. 43 
6.7.1 Handling of study treatment and additional treatment  .......................... 43 
6.7.2 Instruction  for prescribing  and taking study treatment  .......................... 44 
7 Informed  consent  procedures  ............................................................................................. 44 
8 Visit schedu le and assessments .......................................................................................... 45 
8.1 Screening  ................................................................................................................ 49 
8.1.1 Information  to be collected  on screening  failures  .................................. 49 
8.2 Participant  demographics/other baseline characteristics ........................................ 49 
8.3 Efficacy  .................................................................................................................. 49 
8.3.1 Primary  efficacy  assessments ................................................................ 50 
8.3.2 Other  efficacy  assessments .................................................................... 51 
8.3.3 Appropriateness of efficacy  assessments ............................................... 51 
8.4 Safety  ..................................................................................................................... 51 
8.4.1 Laboratory  evaluations  .......................................................................... 52 
8.4.2 Electrocardiogram  (ECG)  ...................................................................... 54 
8.4.3 Pregnancy and assessments of fertility  .................................................. 54 
8.4.4 Other  safety  evaluations  ........................................................................ 54 
8.4.5 Appropriateness of safety  measurements .............................................. 55 
8.5 Additional assessments  .......................................................................................... 55 
[COMPANY_001]  Confidential  Page  4 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
  [ADDRESS_148259]-study treatment ........................................................... 58 
10 Safety  monitoring and reporting  ........................................................................................ 59 
10.1 Definition  of adverse events and reporting  requirements  ...................................... 59 
10.1.1 Adverse events ....................................................................................... 59 
10.1.2 Serious adve rse events  ........................................................................... 60 
10.1.3 SAE  reporting  ........................................................................................ 61 
10.1.4 Pregnancy reporting  ............................................................................... 62 
10.1.5 Reporting of study treatment errors  including misuse/abuse ................. 62 
10.2 Additional Safety  Monitoring  ................................................................................ 63 
10.2.1 Liver  safety  monitoring  ......................................................................... 63 
10.2.2 Renal  safet
y monitoring ......................................................................... 64 
10.2.3 Steering  Committee  ............................................................................... 64 
11 Data  Collection  and Database management ....................................................................... 64 
11.1 Data  collection  ....................................................................................................... 64 
11.2 Database management  and quality  control  ............................................................ 65 
11.3 Site monitoring  ....................................................................................................... 66 
12 Data  analysis and statistical  methods  ................................................................................. 67 
12.1 Analysis sets ........................................................................................................... 67 
12.2 Participant demographics and other baseline characteristics ................................. 68 
12.3 Treatments  .............................................................................................................. 68 
12.4 Analysis supporting primary  objectives  ................................................................. 68 
12.4.1 Definition  of primary  endpoints  ............................................................ 68 
12.4.2 Statistical model, hypothesis, and method of analysis  .......................... 68 
12.4.3 Handling of intercurrent events of primary  estimand  ............................ 70 
12.4.4 Handling of missing  values not related  to intercurrent event  ................ 70 
12.4.5 Sensitivity  analyses  ............................................................................... 70 

[COMPANY_001]  Confidential  Page  5 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
12.4.6 Supplementary analysis  ......................................................................... 70 
12.4.7 Supportive analyses  ............................................................................... 71 
12.5 Analysis supporting secondary  objectives  .............................................................. 71 
12.5.1 Efficacy  and/or Pharmacodynamic endpoint(s)  ..................................... 71 
12.5.2 Safety  endpoints  .................................................................................... 72 
12.5.3 Pharmacokinetics ................................................................................... 73 
12.5.4 DNA  ...................................................................................................... 73 
12.5.5 Biomarkers  ............................................................................................ 73 
12.5.6 PK/PD  relationships  .............................................................................. 73 
  73 
  73 
12.7 Interim  analyses  ..................................................................................................... 74 
12.8 Sample  size calculation  .......................................................................................... 74 
12.8.1 Primary  endpoint(s)  ............................................................................... 74 
12.8.2 Secondary endpoint(s)  ........................................................................... 75 
13 Ethical considerations and administrative  procedures  ....................................................... 75 
13.1 Regulatory and ethical  compliance  ........................................................................ 75 
13.2 Responsibilities of the investigator and IRB/IEC  .................................................. 75 
13.3 Publication  of study protocol and results  ............................................................... 76 
13.4 Quality  Control and Quality  Assurance ................................................................. 76 
14 Protocol adherence  ............................................................................................................. 76 
14.1 Protocol
 amendments  ............................................................................................. 77 
15 References  .......................................................................................................................... 78 
16 Appendices  ......................................................................................................................... 82 
16.1 Appendix 1: Clinically  notable laboratory  values and vital signs  .......................... 82 
16.2 Appendix 2: Liver event and laboratory trigger definitions & follow-up 
requirements  ........................................................................................................... 83 
16.3 Appendix 3: Specific Renal  Alert Criteria  and Actions and Event  Follow- up ...... 86 
16.4 Appendix 4: Sampson Criteria  for Diagnosing Anaphylaxis  ................................. 88 
  89 
  91 

[COMPANY_001]  Confidential  Page  6 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
List of tables  
Table  2-1 Objectives and related  endpoints  ........................................................... 26 
Table  6-1 Investigational and control drug ............................................................ 38 
Table  6-2 Prohibited medication  ............................................................................ 39 
Table 6 -3 Guidance on specific clinical and diagnostic assessments which 
can be performed to rule out possible alternati ve causes of  
observed LFT abnormalities  .................................................................. 42 
Table  6-4 Dose  and treatment schedule  ................................................................. 44 
Table  8-1 Assessment  Schedule  ............................................................................. 47 
Table  8-2 Safety  Assessment  ................................................................................. 52 
Table 10-1 Guidance for capturing the study treatment errors including 
misuse/abuse .......................................................................................... [ADDRESS_148260] of figures  
Figure 3-1 Study Design  ......................................................................................... 30 
[COMPANY_001]  Confidential  Page  7 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
List of abbreviations  
ACC American  College  of Cardiology  
ACE Angiotensin  Converting  Enzyme  
AE Adverse  Event  
AHA American  Heart  Association  
ALP Alkaline  Phosphatase  
ALT Alanine  Aminotransferase  
ApoB  Apolipoprotein  B 
ARB Angiotensin  II Receptor  Blockers  
ASCVD  Atherosclerotic  Cardiovascular  Disease  
AST Aspartate  Aminotransferase  
ATC Anatomical  Therapeutic  Chemical  
  
BP Blood  Pressure  
BUN Blood  Urea  Nitrogen  
CABG  Coronary  Artery  By[CONTACT_131321]&PS  Chief  Medical  Office  and Patient  Safety  
  
COVID -19 Coronavirus  Disease  2019  
CPK Creatinine  Phosphokinase  
CRA Clinical  Research  Associate  
CRF Case  Report/Record  Form  (paper  or electronic)  
CRO  Contract  Research  Organization  
CT Computerized  Tomography  
CTA Computed  Tomography  Angiography  
CV Cardiovascular  
CVD Cardiovascular  Disease  
DIN Drug  Inducted  Nephrotoxicity  
dL Decilitre  
DNA Deoxyribonucleic  Acid 
ECG  Electrocardiogram  
eCRF  Electronic  Case  Report  Form  
EDC Electronic  Data  Capture  
eGFR  Estimated  Glomerular  Filtration  Rate 
EHR Electronic  Health  Record  
EMA  European  Medicines  Agency  
eTMF  Electronic  Trial Master  File 
FAS Full Analysis  Set 
FDA Food  and Drug  Administration  
g Gram  

[COMPANY_001]  Confidential  Page  8 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
GalNAc  N-Acetylgalactosamine  
GCP  Good  Clinical  Practice  
GDMT  Guideline -Directed  Medical  Therapy  
GGT  Gamma -Glutamyl  Transferase  
GLDH  Glutamate  Dehydrogenase  
GPP Good  Pharmaceopi[INVESTIGATOR_131266]  B Core  Antibody  
HBsAb  Hepatitis  B Surface  Antibody  
HBsAg  Hepatitis  B Surface  Antigen  
HBV Hepatitis  B Virus  
hCG Human  Chorionic  Gonadotropin  
HCV Hepatitis  C Virus  
HDL-C High Density  Lipoprotein  Cholesterol  
HRSA  Health  Resources  and Services  Administration  
NYHA  [LOCATION_001] Heart  Association  
IUD Intrauterine  Device  
IB Investigator’s  Brochure  
ICF Informed  Consent  Form  
ICH International  Council  for Harmonization of Technical  Requirements  for Pharmaceuticals 
for Human Use  
IEC Independent  Ethics  Committee  
IN Investigator  Notification  
INR International  Normalized  Ratio  
IRB Institutional  Review  Board  
IRT Interactive  Response  Technology  
ISR Injection  Site Reaction  
LDH Lactate  Dehydrogenase  
LDL-C Low-Density  Lipoprotein  Cholesterol  
LFT Liver  Function  Test 
LLN Lower  Limit  of Normal  
LNP Lipid  Nanoparticle  
Lp(a)  Lipoprotein  (A) 
MACE  Major  Adverse  Cardiovascular  Events  
  
MCH  Mean  Corpuscular  Hemoglobin  
MCHC  Mean  Corpuscular  Hemoglobin  Concentration  
MCV  Mean  Corpuscular  Volume  
MDCT  Multidetector  Computed  Tomography  
MedDRA  Medical  Dictionary  for Regulatory  Activities  
mg Milligram(s)  

[COMPANY_001]  Confidential  Page  9 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
MI Myocardial  Infarction  
mL Milliliter(s)  
MMRM  Mixed -Effects  Model  Repeated  Measures  
MRI Magnetic  Resonance  Imaging  
mRNA  Messenger  Ribonucleic  Acid 
  
non-HDL-C Non-High-Density  Lipoprotein  Cholesterol  
NYHA  [LOCATION_001] Heart  Association  
PAD Peripheral  Arterial  Disease  
PCI Percutaneous  Coronary  Intervention  
PCSK9  Proprotein  Convertase  Subtilisin/Kexin  Type  9 
PFS Pre-filled Syringe  
PI [INVESTIGATOR_131267] -Induced  Silencing  Complex  
RNA Ribonucleic  Acid 
RNA-PCR Reversed  Transcription  and Subsequent  Polymerase  Chain  Reaction  
RBC Red Blood  Cell(s)  
RNAi  Ribonucleic  Acid Interference  
s.c. Subcutaneous  
SC Steering  Committee  
SAE Serious  Adverse  Event  
sCR Serum  Creatinine  
siRNAs  Small  Interfering  Ribonucleic  Acids  
SMQ  Standardized  MedDRA  Query  
SOP Standard  Operating  Procedures  
S[LOCATION_003]R  Suspected  Unexpected  Serious  Adverse  Reaction  
TBL Total  Bilirubin  
  
  
μL Microliter  
U/L Units  per Litre 
ULN Upper  Limit  of Normal  
US United  States  
VLDL -C Very-Low-Density  Lipoprotein  Cholesterol  
WBC  White  Blood  Cell(s)  
WHO  World  Health  Organization  
WoC  Withdrawal  of Consent  

[COMPANY_001]  Confidential  Page  10 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Glossary of terms  
Additional 
treatment  Medicinal  products  that may be used  during  the clinical  trial as described  in 
the protocol, but not as an investigational medicinal product (e.g. any 
background therapy)  
Assessment  A procedure  used  to generate  data required  by [CONTACT_131322]  A biological  specimen including,  for example,  blood (plasma,  serum),  saliva, 
tissue, urine, stool, etc. taken from a study participant  
Clinical  Trial Team  A group of people responsible  for the planning,  execution and reporting  of all 
clinical trial activities. Examples of team members include the Study Lead, 
Medical Monitor, Trial Statistician etc.  
Coded Data Personal  Data  which  has been de-identified by [CONTACT_131323] a code.  
Cohort  A specific  group  of participants  fulfilling  certain  criteria  and generally  treated 
at the same time  
Control  drug A study  drug (active  or placebo) used  as a comparator  to reduce assessment 
bias, preserve blinding of investigational drug, assess internal study validity, 
and/or evaluate comparative effects of the investigational drug  
Discontinuation 
from study  Point/time when the participant permanently stops receiving the study treatment and further protocol required assessments or follow -up, for any 
reason.  No specific  request  is made  to stop the use of their samples  or data.  
Discontinuation from study 
treatm ent Point/time when the participant permanently stops receiving the study 
treatment for any reason (prior to the planned completion of study drug 
administration, if any). Participant agrees to the other protocol required 
assessments  including  follow -up. No specific  request  is made to stop the use 
of their samples or data.  
Dosage  Dose  of the study  treatment  given  to the participant  in a time unit (e.g. 100 mg 
once a day, 75 mg twice a day)  
Electronic  Data 
Capture (EDC) Electronic data capture (EDC) is the electronic acquisition of clinical study data using data collection systems, such as Web -based applications, 
interactive voice response systems and clinical laboratory interfaces. EDC includes  the use of Electronic  Case  Report  Forms  (eCRFs) which  are used to 
capture data transcribed from paper source forms used at the point of care  
End of the clinical 
trial The end of the clinical trial is defined as the last visit of the last participant  or 
at a later point in time as defined by [CONTACT_30761]/time  of participant  entry  into the study  at which  informed  consent  must 
be obtained  
Estimand  A precise description of the treatment effect reflecting the clinical question posed by [CONTACT_6553]. It summarizes at a population-level what the outcomes would be in the same patients under different treatment conditions 
being compared.  Attributes  of an estimand  include the population,  variable (or 
endpoint) and treatment of interest, as well as the specification of how the 
remaining intercurrent events are addressed and a population- level summary 
for the variable.  
Intercurrent  events  Events occurring after treatment initiation that affect either the interpretation or the existence  of the measurements  associated with the clinical  question of 
interest.  

[COMPANY_001]  Confidential  Page  11 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
Investigational 
drug/  treatment  The drug whose  properties  are being tested in the study  
Maximally  tolerated 
statin therapy  Maximally  tolerated statin  therapy  in accordance with the 2018 ACC/AHA 
guidelines  
Medication  number  A unique  identifier  on the label  of medication  kits 
Mis-randomized 
participants  Mis-randomized participants are those who were not qualified for 
randomization and who did not take study  treatment,  but have  been 
inadvertently randomized into the study  
Off-site Describes  trial activities  that are performed at remote location  by [CONTACT_106623]-site 
healthcare professional,  such  as procedures  performed at the participant's 
home.  
Off-site healthcare 
Professional  (OHP)  A qualified healthcare professional, such as a nurse, phlebotomist or 
physician,  who perfor ms certain  protocol  procedures  for the participant  in an 
off-site location such as a participant's home.  
Other  treatment  Treatment  that may be needed/allowed  during  the conduct  of the study  (i.e. 
concomitant or rescue therapy)  
Part A sub -division of a study used to evaluate specific objectives or contain 
different  populations.  For example,  one study  could contain a single  dose  part 
and a multiple  dose  part, or a part in participants  with established disease and 
in those with newly -diagnosed disease  
Participant  A trial participant  (can be a healthy  volunteer  or a patient)  
Participant  number  A unique number assigned to each participant upon signing the informed 
consent.  This number  is the definitive,  unique identifier  for the participant  and 
should be used to identify the participant throughout the study for all data 
collected, sample labels, etc. 
Period  The subdivisions of the trial design (e.g. Screening, Treatment, Follow -up) 
which  are described  in the Protocol.  Periods  define the study  phases  and will 
be used in clinical trial database setup and eventually in analysis  
Personal  data Participant information collected by [CONTACT_131324]. This data includes 
participant identifier information, study information and biological samples.  
Premature participant withdrawal  Point/time when the participant exits from the study prior to the planned completion of all study drug administration and/or assessments; at this time all study  drug administration is discontinued and no further  assessments  are 
planned  
Randomization The process of assigning trial participants to investigational drug or control/comparator drug using  an element  of chance to determine the 
assignments in order to reduce bias.  
Randomization 
number  A unique identifier assigned  to each randomized  participant  
Re-screening  If a participant fails the initial screening and is considered as a Screen Failure,  he/she can be invited once  for a new Screening visit after medical 
judgment and as specified by [CONTACT_131325]  12 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
Remote  Describes any trial activities performed at a location that is not the 
investigative site where the investigator  will conduct  the trial, but is for 
example a home or another appropriate location  
Screen  Failure  A participant  who did not meet  one or more  criteria  that were required  for 
participation in the study  
Source Data/Document  Source data refers  to the initial  record,  document,  or primary  location  from 
where data comes. The data source can be a database, a dataset, a 
spreadsheet or even hard -coded data, such as paper or eSource  
Start  of the clinical 
trial The start of the clinical  trial is defined as the signature [CONTACT_30832] [CONTACT_131326];  includes  investigational 
drug(s), control(s) or background therapy  
Study  treatment 
discontinuation When the participant permanently stops taking any of the study drug(s) prior to the defined study  treatment  completion  date (if any) for any reason;  may or 
may not also be the point/time of study discontinuation  
Tele-visit Procedures  or communications  conducted  using  technology  such  as 
telephone or video- conference, whereby [CONTACT_131327].  
Treatment 
arm/group  A treatment  arm/group  defines  the dose  and regimen  or the combination,  and 
may consist of [ADDRESS_148261],  which  might  or might  not be the same  
as the study  treatment.  
Variable (or 
endpoint)  The variable (or endpoint) to be obtained for each participant that is required 
to address  the clinical  question.  The specification  of the variable  might  include 
whether the participant experiences an intercurrent event.  
Withdrawal  of 
study  consent 
(WoC)  Withdrawal  of consent  from the study  occurs  only when a participant  does  not 
want to participate in the study any longer and does not allow any further 
collection of personal data  
[COMPANY_001]  Confidential  Page  13 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Amendment  02 
Amendment  rationale  
 
The purpose of the clinical study amendment is to clarify the use of inclisiran, which is now 
commercially available as LEQVIO®. Exclusion criteria #[ADDRESS_148262]  the same.  Protocol  Summary  and Section  5 reflects “50”  US sites.  
 
Changes to the protocol  
o Section 3 Study Design: Added “Commercially available inclisiran may be used for 
appropriate patients in the usual care arm at the sole discretion of the treating physician, 
without any influence from the PI.” 
o Protocol Summary  and Section  5: Reflects  a change of “40” sites to “50” US sites.  
o Section 5.2 Exclusion #15: Added “Treatment with monoclonal antibodies directed 
towards PCSK9 or inclisiran within 90 days of screening.” 
 
Amendment  [ADDRESS_148263] and obtain consent from the female partner of any male participant when the female partner becomes pregnant during the study in order to obtain pregnancy outcome information.  
This protocol amendment, finalized prior to study start, will be the initial protocol version submitted to regulatory authorities, including the FDA, and Site IRBs for study approval. 
 
Changes to the protocol  
• Updated list of abbreviations to include Injection  Site Reaction  
• Section  3 added  language ‘if and w hen inclisiran  becomes commercially  available’  and 
changed to ‘approximately’ 40 sites 
• Figure 3-1  removed ‘Baseline’  from  Visit  1 
• Section  6.5.1 revised  dose modif ication  text 
• Section  6.5.2 removed ‘not applicab le’ 
• Section  [IP_ADDRESS] added follow  up on pot ential drug-induced liver injury  (DILI) cases 
• Section [IP_ADDRESS] removed language that participants will be asked to return all unused 
study medication  
• Section  7 
o  
o removed pregnant partner information  

[COMPANY_001]  Confidential  Page  16 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 • To assess plasma lipi[INVESTIGATOR_805], lipoproteins and triglycerides in participants 
receiving an "inclisiran  first" implementation strategy  compared to usual 
care at Day 330  
• To assess  changes  in and adherence to background lipid-lowering  therapy  in 
participants receiving an "inclisiran first" implementation strategy compared 
to usual care at Day 330  
• To assess  visit-to-visit LDL-C variability  from Day 90 until Day 330 
• To assess  overall  safety  and tolerability  of inclisiran  
Study design The study design will be a randomized, two- arm, parallel -group, open- label, 
multicenter, clinical trial comparing an "inclisiran first" implementation strategy to usual  care in approximately  444 participants  (1:1 randomization)  with established 
ASCVD and e levated LDL -C (or non- HDL-C) despi[INVESTIGATOR_131268].  
Study population  The study will include male and female participants ≥18 years of age with a history of ASCVD (coronary heart disease, ischemic cerebrovascular disease or 
peripheral  arterial  disease)  who have  elevated LDL-C (≥70 mg/dL)  or non-HDL-C 
(≥100 mg/dL) despi[INVESTIGATOR_131269]. A total of approximately 444 participants will be randomized to the “inclisiran first” 
implementat ion strategy  or usual  care in a 1:[ADDRESS_148264]  meet  all of the following 
criteria:  
1. Signed informed consent  must  be obtained prior to participation in the 
study  
2. Males  and females  ≥18 years  of age 
3. History of ASCVD,  documented by [CONTACT_2360][INVESTIGATOR_1097], claims data and/or prior 
laboratory/imaging assessments  
a. Coronary  heart  disease 
(CHD):  
• Prior  myocardial 
infarction  
• Prior  coronary  revascularization  (PCI or CABG)  
• Angiographic or CT -imaging (e.g., MDCT/CTA) 
evidence  of coronary  atherosclerosis  (>70%  stenosis 
in at least one major epi[INVESTIGATOR_131270])  
b. Cerebrovascular disease:  
• Prior  ischemic  stroke  confirmed by a brain imaging  study, 
CT orMRI; thought not to be caused by [CONTACT_95041], valvular heartdisease or mural thrombus  
• Carotid artery  stenosis  >70%  on prior angiography  or 
ultrasound  
• History  of prior percutaneous  or surgical  carotid 
arteryrevascularization  
c. Peripheral  arterial  disease (PAD):  
• Prior  documentation of a resting  ankle- brachial  index  ≤0.85 
• History  of prior percutaneous  or surgical  revascularization 
of aniliac, femoral, or popliteal artery or aortic aneurysm  
• Prior non- traumatic amputation of a lower extremity 
due toperipheral artery disease  
4. Serum  LDL-C ≥70 mg/dL or non-HDL-C ≥100 mg/dL  
5. Fasting  triglyceride  <5.65  mmol/L  (<500  mg/dL)  at screening  
[COMPANY_001]  Confidential  Page  17 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 6. Calculated glomerular filtration rate >30 mL/min by [CONTACT_131328] (eGFR) using standardized local clinical methodology  
7. Participants  should be on maximally  tolerated statin  therapy,  as determined by 
[CONTACT_093],  with no immediate  plans  to modify  lipid lowering therapi[INVESTIGATOR_014].  Statin 
intolerant patients are eligible if they had documented side effects on at least [ADDRESS_148265] be willing and able to give informed consent  before initiation 
of any study related procedures and willing to comply with all required study 
procedures  
Key Exclusion criteria  Participants  meeting any of the following  criteria  are not eligible  for inclusion  in 
this study.  
1. Any uncontrolled or serious disease, or any medical or surgical condition, that 
may either  interfere with participation in the clinical  study,  and/or put the participant 
at significant risk (according to investigator’s [or delegate] judgment) if he/she 
participates in the clinical study  
2. An underlying  known  disease,  or surgical,  physical,  or medical  condition that, in 
the opi[INVESTIGATOR_871] (or delegate) might interfere with interpretation of the clinical study results  
3. [LOCATION_001] Heart Association (NY HA) class III or IV heart failure or last known 
left ventricular ejection fraction <30%  
4. Significant  cardiac  arrhythmia  within  3 months  prior to randomization that is not 
controlled by [CONTACT_131329]  
5. Major  adverse  cardiovascular  event  within  6 months  prior to randomization  
6. Uncontrolled severe hypertension: systolic blood pressure >180 mmHg or 
diastolic blood pressure >110 mmHg prior to randomization despi[INVESTIGATOR_131271]  
7. Severe  concomitant  non-cardiovascular  disease that carries  the risk of reducing 
life expectancy to less than 2 years  
8. History of malignancy that required surgery (excluding local and wide- local 
excision), radiation therapy and/or systemic therapy during the two years prior to randomization 
9. Women  of child-bearing potential,  defined as all women  physiologically  capable 
of becoming pregnant, unless they are using basic methods of contraception 
during dosing of investigational drug. Basic contraception methods include:  
a. Total abstinence (when this is in line with the preferred and usual 
lifestyle  of the participant.  Periodic  abstinence (e.g.,  calendar,  ovulation, 
symptothermal, post -ovulation methods) and withdrawal are not 
acceptable methods of contraception  
b. Female  sterilization  (have  had surgical  bilateral  oophorectomy  with or 
without hysterectomy), total hysterectomy or tubal ligation at least six 
weeks before taking investigational drug. In case of oophorectomy 
alone, only when the reproductive status of the woman has been 
confirmed by [CONTACT_104]  
c. Male sterilization (at least 6 m prior to screening). For female participants  in the study,  the vasectomized male  partner  should be the 
sole partner for that participant  
[COMPANY_001]  Confidential  Page  18 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 d. Barrier methods  of contraception:  Condom  or Occlusive  cap (diaphragm 
or cervical/vault caps)  
e. Use of oral (estrogen  and progesterone),  injected or implanted hormonal 
methods of contraception or other forms of hormonal contraception that 
have comparable efficacy (failure rate <1%), for example hormone 
vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS)  
In case  of use of oral contraception,  women  should have been stable on the same 
pi[INVESTIGATOR_6522] a mini mum of [ADDRESS_148266] had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical  profile  (e.g. age appropriate,  history  of vasomotor  symptoms)  or have had 
surgical  bilateral  oophorectomy  (with  or without  hysterectomy),  total hysterectomy 
or tubal ligation at least six weeks ago. In the case of oophorectomy alone, only 
when the reproductive status of the woman has been confirmed by [CONTACT_64063].  
10. Known history of alcohol and/or drug abuse within the last 5 years 
(occasional  casual  users  of illicit drugs  in the opi[INVESTIGATOR_131272])  
11. Treatment  with other  investigational  products  or devices  within  [ADDRESS_148267] 
of the study, such as but not limited to:  
a. Participants  who are unable  to communicate or to cooperate with the 
investigator  
b. Unable to understand the protocol requirements, instructions and study- 
related restrictions, the nature, scope, and possible consequences of the study (including participants whose cooperation is doubtful due to drug abuse or alcohol dependency)  
c. Unlikely to comply with the protocol requirements, instructions, and study- 
related restrictions (e.g., uncooperative attitude, inability to return for 
follow -up visits, and improbability of completing the study – including 
potential participants who indicate that their participation is contingent on receiving inclisiran)  
d. Have any medical or surgical condition, which in the opi[INVESTIGATOR_131273]  
e. Persons  directly  involved in the conduct  of the study  
15. Previous or current treatment (within 90 days of screening) with monoclonal 
antibodies directed towards PCSK9, or with inclisiran or ezetimibe.  
16. Active liver disease defined as any known current infectious, neoplastic, or 
metabolic path ology  of the liver or alanine aminotransferase (ALT) elevation >3x  
[COMPANY_001]  Confidential  Page  19 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 ULN, aspartate aminotransferase (AST) elevation >3x ULN, or total bilirubin 
elevation >2x ULN (except patients with Gilbert’s syndrome) at screening 
confirmed by a repeat measurement at least one week apart  
Study 
treatment  Inclisiran  (KJX839),  284 mg, 1.5 ml Liquid in a single -use prefilled  syringe  (PFS) 
for s.c. administration  
Usual  care per treating  physician  
Treatment of 
interest  An "inclisiran first" implementation strategy (addition of inclisiran to maximally tolerated statin therapy immediately upon failure to reach acceptable LDL- C 
levels  with maximally  tolerated statin  therapy  alone)  compared to usual  care (per 
treating physic ian). 
Efficacy assessments The primary efficacy assessments will be LDL- C and discontinuation of statin 
therapy.  Other  efficacy  assessments  will include  measurement  of Apo B, Lp(a), 
non-HDL-C, VLDL -C, total cholesterol, triglycerides, and HDL -C. 
Key safety 
assessments Safety assessments will consist of monitoring and recording of all adverse 
events  and serious  adverse  events,  evaluation of hematology,  blood chemistry 
and urine values, regular measurement of vital signs and the performance of 
physical examinations.  
Data  analysis The primary  efficacy  variables  are the following:  
1. Percent  change  from baseline in LDL-C 
2. Discontinuation of statin therapy (i.e., no statin use ≥ 30 days before the end- 
of-study visit) (yes, no)  
The primary  analysis  time point  for both primary  efficacy  variables  is at Day 330. 
Primary efficacy variable 1 will be analyzed using mixed -effects m odel repeated 
measures (MMRM) with treatment, visit, baseline,  
 treatm
ent-by-visit interaction, and baseline-by -visit interaction as 
explanatory  variables.  An unstructured  wor king correlation matrix  will be assumed 
for this model.  Least -squares  mean of each  treatment  group,  least -squares  mean 
treatment difference, two- sided 97.5% confidence interval for the treatment 
difference, and p- value based on the fitted MMRM will be reported for each 
applicable visit (day).  If the p -value  based on a two- sided test  for treatment  effect 
at Day 330 is < 0.[ADDRESS_148268] squares mean treatment 
difference ("inclisiran first" implementation strategy – usual care) is less than 0, 
statistical  significance  in favor  of "inclisiran  first" implementation strategy  is shown.  
For primary efficacy variable 2, a one -sided 98.75% confidence interval for 
treatment  difference ("inclisiran first"  implementation strategy  – usual care) in the 
proportion of participants who discontinued statin therapy at Day 330 will be 
computed using the normal approximation to the binomial distribution. Non- 
inferiority of the "inclisiran first" implementation strategy to usual care will be 
declared if the upper limit of the confidence interval does not exceed the non - 
inferiority margin of 15%.  
The secondar
y effica c y variables  are the following:  
1. Absolute  change  from baseline  in LDL-C 

[COMPANY_001]  Confidential  Page  20 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 2. Average percent change from baseline in LDL- C levels to each post -baseline 
visit 
3. Average absolute change from baseline in LDL- C levels to each post -baseline 
visit 
4. Achieving  ≥ 50% reduction from baseline  in LDL-C (yes,  no) 
5. Achieving  LDL-C < 100 mg/dL  (yes, no) (among the subset  of participants  with 
LDL-C ≥ 100 mg/dL at baseline)  
6. Achievi ng LDL-C < 70 mg/dL (yes,  no) 
7. Achieving  LDL-C < 55 mg/dL (yes,  no) 
8. Percent  change  from baseline in apoB  
9. Absolute change from baseline in apoB  
10. Percent  change  from baseline in non-HDL-C 
11. Absolute change  from baseline in non-HDL-C 
12. Percent  change from baseline in VLDL -C 
13. Absolute change from baseline in VLDL -C 
14. Percent  change from baseline in total cholesterol  
15. Absolute change from baseline in total cholesterol  
16. Percent  change from baseline in Lp(a)  
17. Absolute change from baseline in Lp(a)  
18. Percent  change from baseline in HDL-C 
19. Absolute change from baseline in HDL-C 
20. Percent  change  from baseline in triglycerides  
21. Absolute change from baseline in triglycerides  
22. Intensity of lipid- lowering therapy (decrease in dose, no change in dose, 
increase in dose)  
23. Proportion of days covered (total number of days on either statin, ezetimibe, 
bempedoic acid or PCSK9 inhibiting monoclonal antibody therapi[INVESTIGATOR_131274])  
Analyses  of secondary  efficacy  variables  1 and 8 - 21 will be similar  to the primary 
analysis of primary efficacy variable 1 (using MMRM, but with a two- sided 95% 
confidence interval for the treatment difference).  
Secondary  efficacy variable  2, 3, and 23 will be analyzed using a linear  model  with 
treatment, baseline LDL -C, and  as 
explanatory variables.  
Secondary efficacy variables 4 - 7 will be analyzed at each time point using a 
logistic  regression  model  with treatment,  baseline LDL-C,  
 as explanatory variables.  
Secondary efficacy variable 22 will be analyzed at each time point using a 
proportional odds model  with treatment,  baseline LDL -C, and  
 as explanatory variables.  

[COMPANY_001]  Confidential  Page  21 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 Visit-to-visit LDL -C variability from  Day 90 until Day 330 will be reported, using 
various measures of variability (standard deviation, coefficient of variation).  
Key words  Hyperlipi[INVESTIGATOR_035], Secondary Cardiovascular Prevention, Atherosclerotic 
Cardiovascular  Disease  (ASCVD),  Hypercholesterolemia,  Lipid  lowering 
therapi[INVESTIGATOR_131275]  22 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
1 Introduction  
1.1 Background  
Inclisiran is a novel synthetic small interfering ribonucleic acid (siRNA) therapeutic for 
subcutaneous (s.c.) injection for the treatment of hypercholesterolemia. Inclisiran has been shown to lower low density lipoprotein cholesterol (LDL -C) by 50% or more in patients with 
established atherosclerotic cardiovascular disease (ASCVD) who are treated with maximally tolerated statin therapy compared to placebo in randomized, double -blind, placebo -controlled 
trials (Ray et al 2020 ). 
This protocol describes a trial to evaluate the effectiveness of an "inclisiran -first" 
imple
mentation strategy (i.e., initiation of inclisiran immediately after failing to reach 
acceptable LDL -C levels with maximally tol erated statin therapy alone, before addition of 
ezetimibe)  compared to usual care without inclisiran  in a population with AS
CVD  
. This study will be c onducted in compliance with 
Good Clinical Practice s (GCP) and Good Pharmaceopi[INVESTIGATOR_61272] (GPP), including 
the Declaration of Helsinki and all applicable regulatory requirements.  
 
1.1.1  Atherosclerotic cardiovascular  disease (ASCVD)  
Despi[INVESTIGATOR_76572], cardiovascular disease (CVD) is the leading cause of death worldwide, resulting in approximately 18 million deaths annually ( Roth et al 2017 ). Eighty 
percent of all CVD deaths are due to coronary heart disease (CHD) or strokes. Elevated LDL - 
C is a major risk factor for the development of CVD ( Grundy et al 2019).  Lowering LDL -C has 
been shown to r educe the risk of CHD and strokes and the clinical risk reduction is linearly 
proportional to the absolute LDL -C reduction without an apparent threshold below which 
further lowering  yields  no further benefit ( Giugliano et al 2017 ; Baigent et al 2010).  Moreover, 
large trials combined with evidence from studies of people with genetically- determined lower 
LDL -C have confirmed  the safety  of exposure to low levels of LDL -C over long periods  of time 
(Cohen et al 2006; Giugliano et al 2017).  
Approximately 30 million  people in the United  States are treated  with  lipid lowering  therapi[INVESTIGATOR_014], 
predominantly statins, to lower LDL -C and the associated risk of ASCVD ( Wong et al 2016). 
The 2018 American College of Cardiology (ACC) / American Heart Association (AHA) cholester ol guidelines recommend a step -wise algorithm for LDL -C lowering in patients with 
established ASCVD ( Grundy et al 2019). Briefly, all ASCVD patients should be treated with 
high intensity statin therapy. If LDL -C remains 70 mg/dL or higher, ezetimibe can be 
considered. If LDL -C remains  70 mg/dL or higher despi[INVESTIGATOR_131276], 
addition of a PCSK9 inhibiting monoclonal antibody can be considered in very high risk patients (Grundy et al 2019). The position of PCSK9 inhibiting monoclonal antibodies after 
ezetimibe is partially due to the high price of those therapi[INVESTIGATOR_131277] ( Grundy et al 2019). Nonetheless, ezetimibe lowers LDL -C 
by [CONTACT_131330] 20% and therefore  many patients  may still have  elevated  LDL -C despi[INVESTIGATOR_131278] -ezetimibe combination therapy, while many more patients would be able to reach 
acceptable LDL -C levels if more potent LDL -C lowering therapi[INVESTIGATOR_131279]. This would also reduce the problem of polypharmacy. 

Nova rtis Confidential  Page  23 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Additional contributing factors responsible for the fact that only a minority of patients with 
ASCVD have LDL -C levels <70 mg/dL include suboptimal guideline implementation,  inability 
to tolerate statins at sufficiently high doses, poor adherence to therap ies, and system barriers 
such as high cost of therapy ( Wong et al 2016; Lowenstern  et al 2018; Fitchett  et al 2015; Mann  
et al 2010 ; Poluzzi et al 2008; Cannon et al 2020).  
These and other factors are responsible for the fact that the trend in t he [LOCATION_002] (US) of 
lower CV morbidity and mortality observed between [ADDRESS_148269] recent data show an increase in CV mortality ( Virani et al 2020 ). 
 
1.1.2  Mechanism  of RNA  interference  
Ribonucleic acid interference  (RNAi)  is a naturally  occurring cellular  mechanism  for regulating 
gene expression that is mediated by [CONTACT_131331] (siRNAs). Typi[INVESTIGATOR_897], synthetic siRNAs are 19 -base to 25 -base pair double -stranded oligonucleotides in a staggered 
duplex with a two- to four-nucleotide overhang at one or both  of the 3’ ends.  Such  siRNAs  can 
be designed to target  an endogenous messenger  RNA  (mRNA)  transcript  of a given  gene.  When 
introduced into cells,  the guide (or antisense)  strand  of the siRNA  loads into an enzyme complex 
called  the RNA -Induced Silencing  Complex (RISC).  This enzyme complex  subsequently binds 
to its complementary mRNA sequence, mediating cleavage of the target mRNA and the suppression of the target protein encoded by [CONTACT_76612] ( Elbashir et al 2001 ). 
Since unmodified siRNAs are rapi[INVESTIGATOR_131280] ( Soutschek  et al 2004), various formulations are 
currently used to target their distribution to tissues, and to facilitate uptake of siRNAs into the relevant cell type. One approach that has been used successfully in vivo, in animal models (including in rodents and nonhuman primates) and humans employs intravenous delivery of siRNA  in lipid nanoparticle  (LNP)  formulations 
(Soutschek et al 2004; Morrissey  et al 2005; Geisbert  et al 2006; Zimmermann  et al 2006; Coe  
lho et al 2020; Tabernero et al 2013). Another approach for liver -specifi
 c gene silencing is 
subcutaneously administered siRNA conjugated to a N -acetylgalactosamine (GalNAc) 
carbohydrate ligand ( Ashwell  and Morell  1974).  Conjugation of a triantennary  GalNAc  ligand 
to an siRNA enables hepatocyte binding and subsequent cellular uptake via the asialoglycoprotein  receptor,  resulting  in engagement of the RNAi  pathway and down regulation 
of hepatic proteins. 
 
1.1.3  Inclisiran  
Inclisiran is a chemically synthesized, subcutaneously administered, double -stranded siRNA, 
conjugated on the sense strand with triantennary GalNAc to facilitate uptake specifically by [CONTACT_6566] ( Khvorova 2017). In hepatocytes, inclisiran utilizes the RNAi mechanism and 
directs catalytic breakdown of mRNA for PCSK9. This increases LDL -C receptor recycling 
and expression on the hepatocyte cell surface,  which  increases LDL -C uptake and lowers  LDL - 
C levels in the circulation. Inclisiran is now approved by [CONTACT_131332].  
Nova rtis Confidential  Page  24 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
1.1.[ADDRESS_148270] side effects which are reflected  by [CONTACT_131333] ( Ray et al 2020).  For example,  GalNAc  ligands were  added to the RNA strands in order 
to target  inclisiran  to receptors on hepatocytes,  thereby [CONTACT_131334]. This is highlighted by [CONTACT_131335], 
inclisiran exposure in other tissues was 36 - to 1076- fold lower than liver.  
In addition, once inclisiran is inside the cell, there is a low likelihood of off -target binding 
because inclisiran is sequestered wit hin RISC and guided to its complementary mRNA 
sequence which  is highly conserved  across diverse ethnic and geographical  populations  (Ray 
et al 2020). The specificity of the active antisense strand of inclisiran was determined by 
[CONTACT_746] a comprehensive search against the human transcripto me using an exhaustive 
“brute- force”  algorithm implemented  in the python script  ‘BruteForce.py’.  The search  revealed 
20 possible off -target transcripts, two of which are not normally expressed in liver cells. The 
other 18 transcripts were subsequently assayed in an in vitro study to experimentally assess their response to inclisiran.  The 18 gene transcripts were  transfected  into liver cells along with 
inclisiran and expression analysis indicated a ≥45 -fold difference between the “on target” 
suppression of P CSK9 and the suppression of any of the “off- target” transcripts.  
Inclisiran was well tolerated in all animal studies. The most common findings were related to the expected pharmacological effects of inclisiran on lipid profiles and histopathological findin gs of vacuolation in hepatocytes of rats and lymph node macrophages of monkeys and 
the presence of basophilic granules in hepatocytes of monkeys and kidneys of rats. These microscopic findings are not considered adverse effects because they are not associated with changes in clinical pathology parameters. Liver function enzymes were only minimally to mildly increased, and were reversible following treatment- free periods, and there were no 
changes in urinalysis or urine chemistry parameters.  
 
1.1.5  Clinical  studie s 
Inclisiran lowers LDL -C for sustained periods while only requiring twice yearly injections 
resulting in effective reductions in LDL -C (50% or more) in stable ASCVD patients. In the 
double- blind, placebo- controlled, multicenter Phase III ORION trials, inv olving 3,655 
participants (about half of whom received inclisiran, n=1,833), after the initial administration of inclisiran, LDL -C levels were quickly reduced with more than 75% of patients reaching an 
LDL -C <70 mg/dL when  used on top of a maximally  tolerated  statin  (Ray et al 2020).  Adverse 
events in the Phase III trials were generally similar in the inclisiran and placebo groups, although injection -site adverse events were mo re frequent with inclisiran than with placebo; 
such reactions were generally mild, and none were severe or persistent.  
 
1.[ADDRESS_148271] provided high -quality evidence supporting the efficacy, 
safety and tolerability of inclisiran compared to placebo on top of maximally tolerated statin therapy with or without ezetimibe. The clinical value of systematic implementation of an "inclisiran  first" strategy  (addition of inclisiran  to maximally  tolerated  statin  therapy  
Nova rtis Confidential  Page  26 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
2 Objectives,  endpoints  and estimands  
Table 2-1 Objectives  and related  endpoints  
 
Objective(s)  Endpoint(s)  
 
Primary  objective(s)  Endpoint(s) for primary objective(s)  
• To assess  the effect  on LDL-C of an "inclisiran - 
first" implementation strategy compared to 
usual care at Day 330 in participants with ASCVD and an LDL- C ≥70 mg/dL despi[INVESTIGATOR_131281]  
• To assess  the non-inferiority  of an "inclisiran 
first" implementation strategy compared  
to usual  care on discontinuation of background 
statin therapy at Day 330  • Percent  change from baseline in LDL-C 
 
 
 
• Discontinuation of statin  therapy  (i.e., no 
statin use ≥ 30 days before the end- of- 
study visit) (yes, no)  
 
 
Secondary objective(s)  Endpoint(s) for secondary objective(s)  
• To assess  the absolute change in LDL-C of an 
"inclisiran first" implementation strategy 
compared to usual  care at Day 330, as well as 
average of percent and absolute changes in 
LDL-C levels to each post -baseline visit  
 
• To assess the proportion of participants 
reaching  pre-specified  LDL-C targets  among 
those receiving an "inclisiran first" 
implementation strategy compared to usual 
care at Day 330  
 
 
 
• To assess plasma  lipi[INVESTIGATOR_805],  lipoproteins  and 
triglycerides in participants receiving an 
"inclisiran first" implementation  
strategy  compared to usual  care at Day 330 
 
    
 
    
 
• To assess changes  in and adherence to 
background lipid- lowering therapy in 
participants  receiving an "inclisiran first"  • Absolute change from baseline in LDL-C 
• Average percent  change from baseline in 
LDL-C levels to each post -baseline visit  
• Average absolute  change from baseline 
in LDL -C to each post -baseline visit  
• Achieving  ≥ 50% reduction from baseline 
in LDL -C (yes, no)  
• Achieving  LDL-C < 100 mg/dL  (among 
the subset of participants with LDL- 
C >100  mg/dL  at baseline)  (yes, no) 
• Achieving  LDL-C < 70 mg/dL (yes,  no) 
• Achieving  LDL-C < 55 mg/dL (yes,  no) 
• Percent  change and absolute change 
from baseline in apoB  
• Percent  change and absolute change 
from baseline in non- HDL-C 
• Percent  change and absolute change 
from baseline in VLDL-C 
• Percent  change and absolute change 
from baseline in total cholesterol  
• Percent  change and absolute change 
from baseline in Lp(a)  
• Percent  change and absolute change 
from baseline in HDL -C 
• Percent  change and absolute change 
from baseline in triglycerides  
• Intensity of lipid lowering therapy 
(decrease  in dose,  no change in dose, 
increase in dose)  
Nova rtis Confidential  Page  27 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
Objective(s)  Endpoint(s)  
implementation  strategy  compared to usual 
care at Day 330  
 
 
 
• To assess  visit-to-visit LDL-C variability  from 
Day 90 until Day 330  
• To assess  overall  safety  and tolerability  of 
inclisiran  • Proportion of days covered (total number 
of days on either statin, ezetimibe, bempedoic acid or PCSK9 inhibiting 
monoclonal  antibody  therapi[INVESTIGATOR_131282])  
• LDL-C measures  of variability  (standard 
deviation, coefficient of variation) 
• Adverse  events  
 
 
 
 
  
 
 
 
 
 
 
2.[ADDRESS_148272] the interpretation of the trial 
results (e.g., premature discontinuation of treatment). 
The primary  clinical question of interest  is: 
What  is the effectiveness of an "inclisiran  first"  implementation  strategy  compared to usual care 
in patients who have not reached  their LDL -target despi[INVESTIGATOR_12847] a maximally  tolerated 
statin? Inclisiran will be added to maximally tolerated statin therapy and will be compared to 
usual care. Eligible participants will have established ASCVD and elevated LDL -C despi[INVESTIGATOR_131283]9 
inhibiting monoclonal antibodies. Although at baseline there  should be no plans to modify  

Nova rtis Confidential  Page  28 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
background lipid -lowering therapy, the participants’ treating physicians are recommended to 
treat patients  in accordance with the 2018 ACC/AHA cholesterol  guideline ( Grundy et al 2019).  
The justification for the primary estimands is that these will capture both the effects of the 
inclisiran and the effect of changes in, adherence to, and discontinuation of additional medications, mirroring the conditions in clinical practice. Further details can be found in Section 12  
Primary  estimand  1: The primary  analysis of primary  efficacy  variable  1 (percent  change from 
baseline in LDL -C) to address the primary objective will be based on the following estimand: 
• Population: Defined  through appropriate inclusion/exclusion  criteria  to reflect the 
targeted population  
• Variable:  Percent  change from baseline in LDL -C [The  primary  analysis time point is 
at Day 330.]  
• Treatment:  "Inclisiran  first"  implementation  strategy  or usual  care. 
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent  event  will be ignored in the analysis,  as the design 
of the trial allows  for participants in the usual care group to potentially use inclisiran.  
2. Discontinuation  of study  treatment.  This intercurrent event  will be ignored in the 
analysis.  
• Summary  measure:  Least -squares mean  difference  between  "inclisiran  first" 
implementation strategy and usual care  
Primary estimand 2: The primary analysis of primary efficacy variable 2 (discontinuation of statin therapy) to address the primary objective will be based on the following estimand: 
• Population: Defined through appropriate inclusion/exclusion criteria to reflect the targeted  population and if a participant was not statin  intolerant at the beginning of the 
trial 
• Variable:  Discontinuation  of statin  therapy  (yes,  no) [The  primary  analysis time point 
is at Day 330.]  
• Treatment:  "Inclisiran  first"  implementation  strategy  or usual  care. 
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131336]. This intercurrent  event  will be ignored in the analysis,  as the design 
of the trial allows  for participants in the usual care group to potentially use inclisiran.  
2. Discontinuation  of s
 tudy treatment.  This intercurrent event  will be ignored in the 
analysis.  
• Summary  measure:  Treatment difference  ("inclisiran  first" implementation  strategy  – 
usual care) in the proportion of participants who discontinue statin therapy 
Nova rtis Confidential  Page  30 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
The sponsor will  not provide access to therapi[INVESTIGATOR_131284] (only for patients 
randomized to the “inclisiran  first”  implementation strategy  group). In both groups, laboratory 
assessments (including LDL -C) will be performed at screening, Day 0, Day 90, Day 180, D ay 
270 and Day 330. The results of the laboratory assessments performed as part of the trial will 
be available tothe participants' physicians in both study groups. Hence, to minimize reporting bias, participants in the "inclisiran  first"  implementation  group and participants  in the usual care 
group will havean equivalent number of study visits,  and an equivalent number of blood draws 
(including LDL- C tests).  
The study will identify  approximately [ADDRESS_148273] a principal 
investigator (PI) who is responsible for study visits,  while  all aspects of the participants'  routine 
care will remain the responsibility of the participants' own treating physician in both groups. While it is expected that most patients will have a treating physician who is distinct from the PI, a PI [INVESTIGATOR_131285] (temporarily) 
transition  routine  care to a separate physician. This will reduce the effect  that trial participation 
might have on treatment decisions if the PI [INVESTIGATOR_131286] (e.g., more aggressive treatment due to more frequent touchpoints). 
Since  inclisiran  is commercially  available in the US as of late-2021, utilization  of it in the usual 
care group at the sole discretion of the treating physician will  not be encouraged, but will also 
not be prohibited to avoid withholding of appropriate care.  If treatment  with a PCSK9 -inhibiting 
monoclonal antibody was initiated  and a patient would have to be transitioned to inclisiran,  the 
PCSK9 - inhibiting monoclonal antibody should be discontinued. 
The collection  of data from  trial sites through eCRFs  will be complemented with EHR data and 
claims data (e.g., lipid measurements and co ncomitant medications).  
Participants randomized to “inclisiran first” implementation strategy group will receive 
inclisiran at Day 0, Day [ADDRESS_148274]  with blood 
draws  and/or study medication  administration  if required at these visits.  Informed  consent forms 
will be available in English and Spanish. 
 
Figure  3-1   Study Design  
 
Nova rtis Confidential  Page  31 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Remote procedures  
At the Investigator's direction and based on benefit -risk considerations of the participant's 
clinical  condition, qualifying participants  may be offered  the option to have  certain  clinical  trial 
procedures (according to Table 8 -1 Assessment schedule) performed at a remote location.  
Procedures will be performed remotely under the oversight of the Investigator, who retains 
accountability  for the oversight  and all efficacy  and safety  decisions with delegation of tasks  to 
an off- site healthcare professional.  
The remote procedures will be offered at certain sites as determined by [CONTACT_131337]. 
If allowable by a local  Health  Authori ty and depending on operational capabilities,  phone calls, 
virtual contacts (e.g. tele consult) or visits by [CONTACT_131338]´s 
home, can replace on -site study visits for the duration of the disruption until it is safe for the 
participant to visit the site again. Any off -site healthcare professionals utilized during the trial 
must be agreed with [COMPANY_001] before use. In addition to procedures performed by [CONTACT_22885] -site 
healthcare professional, the on -site staff will perform certain procedures remotely using tele - 
visits.  
 
4 Rationale 
4.1 Rationale  for study  design  
Participants with established ASCVD are at increased risk of (recurrent) ischemic events. Lowering LDL -C reduces the risk of  CV events in patients with ASCVD, with a magnitude of 
clinical benefit that is proportional to the redu ction in LDL -C levels ( Giugliano et al 2017). In 
view of the high risk of (recurrent) events in patients  with established  ASCVD and the fact that 
the majority  of patients with established  ASCVD  have elevated  LDL -C despi[INVESTIGATOR_131287], addition of better or less frequently administered non- statin therapi[INVESTIGATOR_131288].  
This trial will compare  an "inclisiran  first"  implementation  strategy  to usual  care.  The Phase III 
trials, which were designed to test the efficacy and safety of inclisiran, compared inclisiran to placebo. Neither  changes in background lipid-lowering  therapy, nor LDL -C tests,  were  allowed 
in those trials. Given the availabilit y of non- statin LDL -C lowering therapi[INVESTIGATOR_131289] -C tests are performed in routine care to assess adherence and 
to guide therapeutic management, a comparison with usual care which may include other non - 
statin therapi[INVESTIGATOR_131290].  
Clinical treatment guidelines recommend addition of non- statin LDL -C lowering therapi[INVESTIGATOR_131291] -C ≥70 mg/dL despi[INVESTIGATOR_131292] 
(Grundy et al 2019). Non- statin therapi[INVESTIGATOR_131293] 2018 ACC/AHA 
cholesterol  guidelines include ezetimibe  and PCSK9 -inhibiting  monoclonal antibodies. In large 
part due to the high costs and inconvenience of administration  of PCSK9  inhibiting monoclonal 
antibodies, the guidelines recommend  initial use of ezetimibe  and addition of PCSK9  inhibiting 
monoclonal antibodies only in very high risk patients who fail to reach  acceptable LDL -C levels  
Nova rtis Confidential  Page  34 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
4.3 Rationale  for choice  of control  drugs  (comparator/placebo)  or 
combination drugs  
Not applicable.  
 
4.4 Purpose  and timing  of interim  analyses/design  adaptations  
After all participants  complete their baseline visit,  the demographic and baseline characteristics 
may be summarized to help design new studies.  
 
4.5 Risks  and benefits  
Appropriate eligibility  criteria  and specific dose- limiting  toxicity  definitions,  as well as specific 
dose modification and stoppi[INVESTIGATOR_004], are included in this protocol. The  risk to participants in 
this trial may be minimized  by [CONTACT_131339], as 
well as close clinical monitoring, and stoppi[INVESTIGATOR_004].  
Participants taking part in this clinical study will receive maximally -tolerated statin therapy 
with or without other  LDL -C lowering  therapi[INVESTIGATOR_014].  Reduction of LDL -C has been  associated  with 
reduced CV risk both by [CONTACT_14198][INVESTIGATOR_76582]. Modification of 
concomitant therapy is at the discretion  of the participants’  treating  physician – participants will 
not be withheld appropriate care. The study may also provide information that may benefit ASCVD patients in the future.  
Support for the  planned administration of inclisiran to participants with elevated LDL -C is 
provided by [CONTACT_716]: 
• Inclisiran  has been  studied in  a Phase III program that  included the population eligible 
for this study.  
• Inclisiran  was considered  to be generally well-tolerated  in Phase III trials  
(Ray et al 2017). Injection site reactions were more frequent in inclisiran -treated 
participants  than in participants  receiving placebo, but were  localized,  predominantly 
mild or occasionally moderate, transient, and resolved without sequelae. 
• The potential for immunogenicity of inclisiran  was shown to be low 
(Landmesser et al 2020).  
• Reduction of LDL -C has been  associated  with reduced CV risk both by [CONTACT_14198][INVESTIGATOR_131294] (Grundy et al 2019).  
An expanded risk-benefit summary  is provided in the Inclisiran  Investigator’s  Brochure (IB). 
Women of child- bear
 ing potential and sexually active males must be informed that taking the 
study treatment may involve unknown risks to the fetus if pregnancy were to occur during the study, and agree that in order to participate in the study they must adhere to the contraception requirements outlined in the exclusion criteria. If there is any question that the participant will not reliably comply, they should not be entered or continue in the study. 
Nova rtis Confidential  Page  35 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
4.6 Rationale  for Public Health Emergency mitigation  procedures  
During a Public Health  Emergency  as declared  by [CONTACT_131340], i.e. pandemic, 
epi[INVESTIGATOR_6519],  mitigation  procedures to ensure participant  safety  and trial integrity 
are listed  in relevant  sections.  Notificat ion of the Public Health  Emergency should be discussed 
with [COMPANY_001] prior to implementation of mitigation procedures, and permitted/approved by 
[CONTACT_6588].  
 
5 Study  Population  
The study will include male  and female  participants  ≥18 years  of age with a history  of ASCVD 
(coronary heart disease, ischemic cerebrovascular disease or peripheral arterial disease) who have elevated LDL -C (≥70 mg/dL) or non- HDL -C (≥100 mg/dL) despi[INVESTIGATOR_131295]. A total of approximately 444 participants will be randomized to the “inclisiran first” implementation strategy or usual care in a 1:[ADDRESS_148275]  meet  all of the following criteria: 
1. Signed informed  consent  must be obtained prior to participation  in the study  
2. Males and females ≥18 years of age 
3. History  of ASCVD,  documented by [CONTACT_2360][INVESTIGATOR_1097],  claims  data and/or prior 
laboratory/imaging assessments  
a. Coronary heart  disease (CHD):  
 Prior myocardial infarction  
 Prior coronary revascularization  (PCI  or CABG)  
 Angiographic or CT-imaging (e.g., MDCT/CTA) evidence of coronary atherosclerosis  (>70% stenosis in at least one major  epi[INVESTIGATOR_131296]) 
b. Cerebrovascular disease:  
 Prior ischemic stroke confirmed  by a brain  imaging  study – CT or MRI;  thought 
not to be caused by [CONTACT_95041], valvular heart disease or mural thrombus  
 Carotid  artery  stenosis >70% on prior angiography or ultrasound  
 History  of pri
 or percutaneous or surgical  carotid  artery  revascularization  
c. Peripheral  arterial  disease  (PAD):  
 Prior documentation of a resting  ankle- brachial  index  ≤0.85  
 History  of prior  percutaneous or surgical  revascularization  of an iliac,  femoral,  or 
popliteal artery or aortic aneurysm  
 Prior non- traumatic  amputation of a lower  extremity  due to peripheral artery 
disease  
4. Serum  LDL -C ≥70 mg/dL or non- HDL -C ≥100 mg/dL  
5. Fasting  triglyceride  <5.65 mmol/L  (<500 mg/dL) at screening  
Nova rtis Confidential  Page  36 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
6. Calculated  glomerular filtration  rate >30 mL/min  by [CONTACT_131341] 
(eGFR) using standardized local clinical methodology  
7. Participants should be on maximally tolerated statin therapy, as determined by [CONTACT_1275],  with no immediate  plans to modify  lipid lowering therapi[INVESTIGATOR_014].  Statin  intolerant 
patients are eligible if they had documented side effects on at least [ADDRESS_148276] be willing  and able to give informed  consent before initiation  of any 
study related procedures and willing to comply with all required study procedures 
 
5.2 Exclusion  criteria  
Participants  meeting  any of the following  criteria  are not eligible  for inclusion  in this study:  
1. Any uncontrolled or serious disease,  or any medical  or surgical condition, that may 
eitherinterfere with participation in the clinical study, and/or put the participant at significant risk (according to investigator’s [or delegate] judgment) if he/she participates in the clinical study 
2. An underlying known disease,  or surgical,  physical, or medical  condition that, in the 
opi[INVESTIGATOR_871] (or delegate) might interfere with interpretation of the clinicalstudy results  
3. [LOCATION_001]  Heart  Association  (NYHA)  class III or IV heart  failure  or last known left 
ventricular ejection fraction <30% 
4. Significant cardiac  arrhythmia  within  3 months prior to randomization  that is not 
controlled by [CONTACT_131329]  
5. Major  adverse cardiovascular  event  within  6 months prior to randomization  
6. Uncontrolled severe hypertension: systolic  blood pressure >180 mmHg or diastolic 
bloodpressure >110 mmHg  prior to randomization  despi[INVESTIGATOR_6521] 
7. Severe concomitant noncardiovascular  disease  that carries the risk of reducing life 
expectancy to less than 2 years  
8. History of malignancy that required surgery (excluding local and wide- local 
excision),radiation therapy  and/or systemic therapy  during the two years prior to 
randomization  
9. Women  of child -bearing  potential, defined  as all women  physiologically capable of 
becoming pregnant, unless they are using basic methods of contraception during dosing ofinvestigational drug. Basic contraception methods include:  
a. Total  abstinence (wh
 en this is in line with the preferred  and usual lifestyle  of the 
participant. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post- ovulation methods) and withdrawal  are not acceptable methods of contraception 
b. Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy),  total hysterectomy or tubal ligation  at least six weeks before  taking 
investigational drug. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_104] 
c. Male sterilization (at least 6 m prior to screening). For female participants in the study, the vasectomized  male  partner should be the sole partner  for that participant  
Nova rtis Confidential  Page  37 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
d. Barrier methods of contraception: Condom or Occlusive cap (diaphragm or 
cervical/vault caps).  
e. Use of oral (estrogen and progesterone), injected or implanted hormonal methods of 
contraception or other  forms  of hormonal contraception  that have  comparable  efficacy 
(failure rate <1%), for example hormone vaginal ring  or transdermal hormone 
contraception or placement of an intrauterine device (IUD) or intrauterine system 
(IUS)  
f. In case of use of oral contraception, women  should have been  stable on the same pi[INVESTIGATOR_131297] [ADDRESS_148277] had 
12 months of natural (spontaneous) amenorrhea  with an appropriate clinical  profile (e.g.  age 
appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with  or without hysterectomy),  total hysterectomy  or tubal ligation  at leastsix  weeks  ago. In 
the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by [CONTACT_6592].  
 
10. Known  history  of alcohol and/or drug abuse within  the last 5 years  (occasional  casual 
users of illicit drugs in the opi[INVESTIGATOR_131298])  
11.  Treatment  with other  investigational products or devices  within  [ADDRESS_148278] of 
the study, such as but not limited to: 
a. Participants  who are unable to communicate or to cooperate with the investigator  
b. Unable to understand the protocol requirements, instructions and study- related 
restrictions, the nature, scope, and possible consequences of the study (including participants  whose cooperation is doubtful due to drug abuse or alcohol dependency) 
c. Unlikely t o comply with the protocol requirements, instructions, and study- related 
restrictions (e.g., uncooperative attitude, inability to return for follow-up visits, and improbability  of completing  the study  – including potential participants  who indicate 
that th eir participation is contingent on receiving inclisiran)  
d. Have  any med
 ical or surgical  condition, which  in the opi[INVESTIGATOR_131299]  
e. Persons directly  involved in the conduct of the study 
15. Previous or current  treatment  (within  90 days of screening)  with monoclonal 
antibodies directed towards PCSK9, or with inclisiran or ezetimibe.  
Nova rtis Confidential  Page  38 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
16. Active  liver disease defined as any known current  infectious,  neoplastic, or metabolic 
pathology of the liver or alanine aminotransferase (ALT) elevation >3x ULN, 
aspartate aminotransferase  (AST)  elevation  >3x ULN,  or total bilirubin  elevation  >2x 
ULN (except patients with Gilbert’s syndrome) at screening confirmed by a repeat measurement at leastone week apart.  
 
 
6 Treatment  
6.1 Study  treatment  
Inclisiran  (KJX839), 284 mg, 1.5 ml liquid  in a single-use PFS  for s.c.  administration. 
Usual care per treating physician  
6.1.1  Investigational  and control  drugs 
 
Table 6-1 Investigational and control drug  
 
Investigational/ 
Control Drug 
(Name  [CONTACT_6673])  Pharmaceutical Dosage Form  Route of Administration Supply Type  Sponsor (global 
or local)  
Inclisiran, KJX839  
284 mg 1.5 ml PFS,  liquid  for 
injection  s.c. Inclisiran  sodium 
300 mg / 1.5 ml  
(equivalent  to 284 
mg of inclisiran)  Sponsor  (local)  
 
6.1.2  Additional  study treatments  
No other treatment beyond investigational drug and usual care are included in this trial. 
 
6.1.3  Treatment  arms/group 
Participants will be assigned at Visit 2/Baseline to one of the following 2 treatment groups ("inclisiran  first"  implementation  strategy  vs usual care)  in a ratio of 1:1 using  a randomization 
process to enroll approximately 444 participants (222 participants per treatment group).  
 
6.1.4  Treatment  duration  
The planned duration of treatment is 330 days from date of randomization.  Participants  may be 
discontinued from treatment at any time due to adverse events, disease progression and/or treatment is discontinued at the discretion of the investigator or the participant.  
 
6.2 Other  treatment(s)  
Not applicable.  
 
6.2.1  Concomitant  therapy  
All prior cardiovascul ar medications (e.g. antiplatelets (i.e. aspi[INVESTIGATOR_248], thienopyridines), 
anticoagulants,  beta-blockers, ACE -inhibitors or  ARBs,  other antihypertensives, antidiabetics, 
and lipid lowering  therapi[INVESTIGATOR_014]) administered  before  the participant is enrolled  in the study  but still 
Nova rtis Confidential  Page  39 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
receiving must be recorded in the appropriate electronic Case Report Forms, or where 
applicable, sourced from the EHR and mapped into the clinical study 
All medications, procedures, and significant non- drug therapi[INVESTIGATOR_014]  (including physical therapy and 
blood transfusions) administered  after the participant is enrolled into the study must be recorded 
on the appropriate electronic Case Report Forms, or where applicable, sourced from the EHR 
and mapped into the clinical study database. 
Each concomitant drug must be individually assessed against all exclusion criteria/prohibited 
medication. If in doubt, the investigator should contact [CONTACT_131342] a participant or allowing a new medication to be started. If the participant is 
already enrolled, contact [CONTACT_131343]. 
 
[IP_ADDRESS]  Permitted  concomitant  therapy requiring caution and/or  action  
Not applicable.  
 
6.2.2  Prohibited medication 
The treatments displayed in the below table are not allowed to be used simultaneously with inclisiran in the active arm but may be prescribed independently via the treating physician’s discretion in the usual care arm.  
 
Table 6-2    Prohibited  medication 
 
Medication  Prohibition  period  Action  to be taken  
Alirocumab  (Praluent)  Participants randomized to inclisiran: monoclonal antibodies directed against PCSK9  are prohibited for the 
full duration of the study  Discontinue PCSK9  inhibitor  
Evolocumab (Repatha)  Participants randomized to 
inclisiran: monoclonal 
antibodies directed against 
PCSK9  are prohibited for the 
full duration of the study  Discontinue PCSK9  inhibitor  
6.[ADDRESS_148279] an in- person screening visit at the 
investigator site.  Each  potential participant who  agrees to  participation  will be identified  in the 
study by a Participant  Number (Participant  No.), that is assigned  when  the participant  is enrolled 
for screening and is retained for the participant throughout his/her participation in the trial. A new Participant No. will be  assigned at every subsequent enrollment if the participant is re- 
screened. The Participant No. consists of the Center Number (Center No.) (as assigned by [CONTACT_5359]) with a sequential participant number suffixed to it, so that each participant’s participation is numbered uniquely across the entire database. Upon signing 
Nova rtis Confidential  Page  40 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
the informed consent form, the participant is assigned to the next sequential Participant No. 
available.  
A new ICF will need  to be signed if the investigator chooses to  re-screen  the participant after  a 
participant has screen failed, and the participant will be assigned a new Participant No.  
 
6.3.2  Treatment  assignment,  randomization  
At visit 2, all eligible participants will be randomized via Interactive Response Technology (IRT) to  one of the two  treatment  groups in  1:1 ratio  ("inclisiran  first" implementation  strategy 
or usual care).  The investigator or his/her  delegate will contact  [CONTACT_131344]/exclusion criteria. The IRT will assign a randomization number to the participant, which will be used to link the participant to a treatment group and will specify  a unique medication  number for the first package  of study treatment to be dispensed 
to the participant. 
The randomization numbers will be generated using the following procedure to ensure that 
treatment assignment  is unbiased. A participant  randomization  list will be produced by [CONTACT_131345] a validated system  that automates the random assignment of participant 
numbers to randomization numbers. These randomization numbers are linked to the different treatment groups, which in turn are linked to medication numbers. A separate medication list will be produced by [CONTACT_90181] a validated  system  that automates  the random assignment of medication  numbers to the package 
containing the investigational drug(s). 
Randomization will be stratified by . The stratification 
ensures bal
anced  allocation  of participants  to treatment groups  within  the strata.  
T
he randomiz
ation scheme for participants will be reviewed and approved by a member of  
the [COMPANY_001] Biometrics group. 
 
6.4 Treatment  blinding 
Not applicable.  
 
6.5 Dose  escalation  and dose modification  
Dose  interruptions  for the investigational study medication  (inclisiran)  are not permitted.  
If a planned dose is missed by [CONTACT_21316] 3 months, administer inclisiran and maintain dosing 
according to the participant’s original schedule. If a planned dose is missed by [CONTACT_726] [ADDRESS_148280] be recorded on the inclisiran Dose Administration case report form for 
the investigational study drug. 
 
6.5.1  Dose  modifications  
Study drug administration of inclisiran [inclisiran (KJX839), 284 mg liquid in PFS, 1.5 ml] should be temporarily interrupted or permanently discontinued in participants with:  

Nova rtis Confidential  Page  42 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
participants without bone metastasis, or elevation of the liver- specific ALP isoenzyme in 
participants with bone metastasis).  
Note: The R value is calculated by [CONTACT_6612], using multiples of the ULN 
for both v
alues. It denotes whether the relative pattern of ALT and/or ALP elevation is due to 
cholestatic (R ≤ 2), hepatocellular (R ≥ 5), or mixed (R >2 and < 5) l iver injury. For children, 
there are caveats to calculating the R -ratio as normal levels of ALP are higher than in adults 
with standard  ranges varying by [CONTACT_131346]. In clinical  situations  where  it is suspected 
that ALP elevations are from an extrahepatic source, the GGT can be used if available. GGT may be less specific than ALP  as a marker  of cholestatic injury, since GGT  can also be elevated 
by [CONTACT_6613]. It is more sensitive than ALP for detecting bile duct injury ( https:
//livertox.nih.gov/rucam.html). 
Table [ADDRESS_148281] (LFT) abnormalities.  
 
Table 6-3 Guidance on specific  clinical and diagnostic  assessments  which  canbe 
performed to rule out possible alternative causes of observed LFT abnormalities  
 
Disease  Assessment  
Hepatitis  A, B, C, E IgM anti-HAV;  HBsAg,  IgM & IgG anti-HBc,  HBV 
DNA;  anti-HCV,  HCV  RNA,  IgM & IgG anti-HEV, 
HEV RNA  
CMV,  HSV,  EBV infection  IgM & IgG anti-CMV,  IgM & IgG anti-HSV;  IgM & 
IgG anti -EBV 
Autoimmune  hepatitis  ANA & ASMA  titers,  total IgM, IgG, IgE, IgA 
Alcoholic  hepatitis  Ethanol  history,  GGT,  MCV,  CD-transferrin  
Nonalcoholic  steatohepatitis  Ultrasound  or MRI 
Hypoxic/ischemic hepatopathy  Medical  history:  acute or chronic  CHF, 
hypotension, hypoxia, hepatic venous 
occlusion. Ultrasound or MRI  
Biliary  tract disease  Ultrasound  or MRI,  ERCP  as appropriate  
Wilson  disease  (if <40 yrs old) Caeruloplasmin  
Hemochromatosis  Ferritin,  transferrin  
Alpha -1-antitrypsin  deficiency  Alpha -1- antitrypsin  
Other causes should also be considered based upon participants’ medical history (hyperthyroidism / thyrotoxic hepatitis – T3, T4, TSH; CVD / ischemic hepatitis – ECG, prior 
hypotensive epi[INVESTIGATOR_1841]; T1D / glycogenic hepatitis). 
Following appropriate causality assessments, as outlined above, the causality of the treatment 
is estimated as “probable” i.e. >5 0% likely, if it appears greater than all other possible causes 
of liver injury combined. The term “treatment- induced” indicates probably caused by [CONTACT_6614],  not by [CONTACT_6615], and only such a case can be considered  a DILI  case and should 
be repor ted as an SAE.  
Nova rtis Confidential  Page  43 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
All cases confirmed on repeat testing meeting the laboratory criteria defined above, with no 
other alternative cause for LFT abnormalities identified, should be considered as “medically significant,”  and thus, meet  the definition  of SAE  and should be reported  as SAE  using the term 
“potential treatment -induced liver injury.” All events should be followed up with the outcome 
clearly documented. 
 
6.6 Additional  treatment  guidance  
6.6.1  Treatment  compliance  
Compliance will be ensured  by [CONTACT_1755]/or study personnel at each dosing visit.  This 
information should be captured in the source document at each visit. Study drug (inclisiran) accountability will also be determined by [CONTACT_131347]. 
Duration  of study drug exposure will be calculated  based  upon the dates  recorded  in the eCRF.  
 
6.7 Preparation and dispensation  
Each  study site will be supplied with study drug in packaging as described  under investigational 
and control drugs section ( Section 6.1.1).  
A unique medication  number is printed  on the study medication  label.  
Investigator staff will identify the study medication kits to dispense to the participant by 
[CONTACT_131348](s). The study medication  has a 2- part 
label (base plus tear -off label), immediately before dispensing the medication kit to the 
participant,  site personnel  will detach  the outer part of the label  from the packaging and affix  it 
to the source document. 
As per Section  4.6, during a Public Health  Emergency  that limits  or prevents on- site study  visits, 
a home health nurse is permitted to administer the study medication at a participant's home (if 
allowed  by [CONTACT_131349]) in the 
event the I nvestigator  has decided  that an on-site visit by [CONTACT_131350]. The dispatch of study medication from the site to the participant’s home remains under the accountability of the Investigator. 
 
6.7.1  Handling of study treatment  and additional  treatment  
 
[IP_ADDRESS]  Handling of study treatment  
Study treatment (inclisiran) must be received by a designated person at the study site, handled and stored  safely  and properly and kept in a secured  location  to which  only the investigator and 
designated site personnel have access. Upon receipt, all study treatment must be stored according  to the instructions specified  on the study  medication  label.  No study medications  will 
be provided for usual care group. 
Clinical supplies are to be dispensed  only in accordance with the protocol. Technical  complaints 
are to be reported to the respective [COMPANY_001] CO Quality Assurance.  
Nova rtis Confidential  Page  44 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Medication labels will include storage conditions for the study treatment but no info rmation 
about the participant except for the medication number . 
The investigator must maintain an accurate record of the shipment and dispensing of study 
treatment in a drug accountability  log. Monitoring of drug accountability  will be performed  by 
[CONTACT_30798].  
At the conclusion of the study, and as appropriate during the course of the study, the investigator 
will return  all unused study  treatment,  packaging, drug labels,  and a copy of the completed  drug 
accountability  log to the [COMPANY_001]  monitor or to the [COMPANY_001]  address provided in the investigator 
folder at each site.  
 
6.7.[ADDRESS_148282] [inclisiran  (KJX839), 284 mg liquid  in PFS,  1.5M ml]  will be provided 
by [CONTACT_456]. Medication labels will comply with regulatory requirements. The storage conditions will be described on the medication label. 
The container closure system  for the prefill ed syringe consists of  a Type I glass syringe with a 
stainless  steel 27G 1/2" staked  needle covered  by a removable  rigid  needle  shield  and Flurotech 
covered bromobutyl plunger. 
 
Table 6-4 Dose and treatment schedule  
 
Investigational  / Control  Drug  
(Name  [CONTACT_131377])  Dose Frequency  and/or Regimen 
Inclisiran  (KJX839),  284 mg 
liquid in PFS, 1.5 ml  Inclisiran  sodium  300 mg/1.5 
ml (equivalent to 284 mg 
inclisiran), s.c. use  Initially,  90 days  later,  180 days 
after the second dose  
Participants  will be administered  a single s.c. injection  of 300 mg inclisiran  sodium for injection 
at predefined time points as described in the Schedule of Assessments ( Table 8 -1). 
Investigational product injection  will be administered  by [CONTACT_131351] r 
the supervision of the investigator or designee. The site of injection is the abdomen, arm or 
thigh. Do not inject into areas of active skin disease or injury such as sunburns, skin rashes, inflammation, tattoos or skin infections.  
All kits of study treatment  assigned  by [CONTACT_131352].  
 
7 Informed  consent  procedures  
Eligible participants may only be included in the study after providing (witnessed, where 
required by [CONTACT_6617]), IRB/IEC-approved informed consent. 
If applicable, in cases where the participant's representative(s) gives consent (if allowed 
accordi ng to local  requirements),  the participant  must be informed  about the study to the extent 
possible given his/her understanding. If the participant is capable of doing so, he/she must 
indicate agreement by [CONTACT_30803]. 
Nova rtis Confidential  Page  45 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Informed  consent  must be obtained before  conducting any study -specific procedures (e.g. all of 
the procedures described in the protocol). The process of obtaining informed consent must be 
documented in the participant source documents. 
[COMPANY_001]  will provide to investigators in a separate  document a proposed informed  consent form 
that complies with the ICH GCP guidelines and regulatory requirements and is considered 
appropriate for this study. Any changes to the proposed consent form suggested by [CONTACT_6619]/IEC.  
Information about common side effects already known about the investigational drug can be 
found in the Investigator's Brochure (IB).  This information  will be included  in the participant 
informed  consent  and should be discussed  with the participant during the study as needed. Any 
new information regarding the safety profile of the investigational drug that is identified between IB updates will be communicated as appropriate, for example, via an investigator notification or an aggregate safety finding. New information might require an update to the informed consent and then must be discussed with the participant. 
The following informed  consents are included in this study:  
• Main  study consent, which  also included:  
- A subsection that requires a separate signature [CONTACT_30833] ‘Optional Consent for 
Additional Research’  to allow  future research  on data/samples collected  during this 
study  
- As applicable, the consent will include language for the use of de- identification and 
tokenization technology that will allow for the acquisition and linkage of the 
participant  to their health  care data that exists in pharmacy and medical  administrative 
claims databases  
• As applicable, Pregnancy Outcomes Reporting Consent for female  participants who took 
study treatment 
Women  of childbearing potential must  be informed  that taking  the study treatment  may involve 
unknown risks to the fetus if pregnancy were to occur during the study and agree that in order 
to participate in the study th ey must adhere to the contraception requirements. 
A copy of the approved version  of all consent forms  must be provided to [COMPANY_001]  after IRB/IEC 
approval.  
Participants  might be asked  to complete an  optional questionnaire to provide feedback  on their 
clinical trial experience.  
 
8 Visit  schedule  and assessments  
The Assessment Schedule ( Table 8 -1) lists the assessments  when they are performed. All data 
obtained from these assessments mus t be supported in the participant’s source documentation. 
Participants should be seen for all visits/assessments as outlined in the assessment schedule (Table  
8-1) or as close to the designat ed day/time  as possible (+/- 7 days). Missed  or rescheduled 
visits should not lead to automatic discontinuation. Participants may be seen at  
Nova rtis Confidential  Page  46 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
any time for an unscheduled visit, e.g., if they experience deterioration or AEs that in the 
opi[INVESTIGATOR_689]/qualified site staff requires closer monitoring.  
Participants who discontinue from study treatment should continue to attend the remain ing 
study visits as indicated in the Assessment Schedule ( Table 8 -1). 
Participants who discontinue from study or withdraw their consent should be scheduled for a final evaluation visit if they  agree, as soon as possible, at which time all of the assessments 
listed for the  final visit will be performed. At this  final visit, all investigational product  should 
be reconciled,  and the adverse event  and concomitant medications not previously reported  must 
be recorded on the eCRF. 
Participants  will have  to comply with the following  restrictions  during the study:  
• Participants need to fast for at least 8 hours for all visits (measurement of 
lipi[INVESTIGATOR_805]/lipoproteins and blood glucose requires participants to be fasting). If the participant  has not fasted,  the collection  of laboratory evaluations must be rescheduled.  
• Blood donation will not be allowed  at any time during the study  
The “X” in the table  denotes the assessments to be recorded  in the clinical  database or received 
electronically from a vendor. The “S” in the table denotes the assessments that are only in the participant’s source documentation and do not need to be recorded in the clinical database. 
As per Section  4.6, during a Public Health  Emergency  that limits  or prevents on- site study  visits, 
alternative methods of providing continuing care may be implemented by [CONTACT_131353]. If allowable by a local Health Autho rity and depending on operational 
capabilities,  phone calls,  virtual contacts (e.g. tele consult) or visits  by [CONTACT_6624]/  home nursing 
staff to the participant´s  home, can replace on- site study visits,  for the duration of the disruption 
until it is safe for the participant to visit the site again.  
[COMPANY_001]  
Amended  Clinical  Trial Protocol  (Version  No. 02) Confidential  Page  47 of 91 
Protocol  No. CKJX839A1US02   
 
Table 8-1 Assessment  Schedule 
 
Epoch  Screening  Treatment1 
Visit  Name  [CONTACT_4838]  1 Baseline/Visit  2 Visit  3 Visit  4 Visit  5 EOS/Visit  6 
Days  -30 to -1 0 90 180 270 330 
Inclusion  / Exclusion  Criteria  X X     
Informed  Consent  X      
Medical  History  X      
ASCVD  Medical  History  X      
Statin  Intolerance  Medical  History  X      
Demography  X      
Pregnancy  and Assessments  of Fertility2 X X X X X X 
Height  and Weight3 X X X X X X 
Vital Signs  X X X X X X 
Physical  Examination4 S  S S S S 
Electrocardiogram  (ECG)  X      
Full Clinical  Chemistry   X    X 
Limited  Clinical  Chemistry  X  X X X  
Hepatitis  Markers  X      
Hematology  X X  X  X 
Coagulation  X X    X 
Urinalysis   X    X 
Lipi[INVESTIGATOR_131300]5 X X X X X X 
Randomization   X     
IRT Transaction  X X X X X X 
Inclisiran  Dose  Administration   X X  X  

[COMPANY_001]  
Amended  Clinical  Trial Protocol  (Version  No. 02) Confidential  Page  48 of 91 
Protocol  No. CKJX839A1US02   
 
Epoch  Screening  Treatment1 
Visit  Name  [CONTACT_4838]  1 Baseline/Visit  2 Visit  3 Visit  4 Visit  5 EOS/Visit  6 
Days  -30 to -1 0 90 180 270 330 
Adverse  Events  X X X X X X 
Injection  Site Reaction  Assessment   X X X X X 
Prior/Concomitant  Medications7 X X X X X X 
Surgical/Medical  Procedures  X X X X X X 
HealthiVibe  Trial Feedback  Questionnaire9  X  X  X 
X Assessment to be recorded in the clinical  database or received electronically  from a vendor  
S Assessment to be recorded in the source documentation only 
[ADDRESS_148283] with blood draws and/or study medication administration if required at this visit.  
[ADDRESS_148284] (hCG)  performed at Visit 1 (central lab). A urine pregnancy  test will be conducted in 
the local laboratory for remaining visits.  
3 Height  only to be performed at Visits  1 and 2 
4 Visits  3, 4 and 5 will be a limited/focused physical  examination.  
5 LDL-C,  apolipoprotein B, Lp(a),  non-HDL-C,  VLDL-C,  total cholesterol,  triglycerides, and HDL-C.  
  
7 30 days  prior to randomization  
  
9 Questionnaire  is optional  for trial participants.  

[COMPANY_001]  Confidential  Page  49 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
8.1 Screening  
A participant who enters screening but is determined not to be eligible will be considered a 
screen failure. It is permissible to re -screen a participant if he/she fails the initial screening; 
however, each case must be discussed and agreed with the Sponsor on a case-by- case basis. If 
the re -screen is approved, a new participant number will be allocated to the participant and 
he/she will need to re -perform all Visit [ADDRESS_148285] provide new written informed consent before they are re- screened.  
 
8.1.1  Information  to be collected on screening failures  
Participants who sign an informed consent form and subsequently found to be ineligible prior 
to randomization will be considered a screen failure. The reason for screen failure should be 
recorded on the appropriate Case Report Form. The demographic informa tion, informed 
consent, and  Inclusion/Exclusion pages must also be completed for screen failure participants. 
No other data  will be entered  into the clinical database for participants who  are screen  failures, 
unless the participant  experienced  a serious adverse  event  during the screening  phase (see SAE 
section for reporting details). The IRT must be notified within 2 days of the screen fail. 
Participants  who are randomized and fail to start treatment,  e.g. participants  randomized in error, 
will be considered an early terminator. The reason for early termination should be recorded on 
the appropriate Case Report Form.  
 
8.2 Participant demographics/other  baseline characteristics  
Patient  demographic and baseline characteristic  data to be collected  on all participants  include: 
age, sex, race,  ethnicity,  type of insurance,  household income  and highest completed  education. 
Relevant  medical  history/current medical  condition  data includes  data collected  up to the point 
in which informed consent is signed. Where possible, diagnoses and not symptoms, will be recorded.  All medications  and relevant  medical  histories  will be recorded  on the corresponding 
eCRFs.  
 
8.3 Efficacy  
The primary  efficacy  variables are the following:  
1. Percent  change from baseline in LDL-C 
2. Discontinuation of statin  therapy (i.e., no statin  script  ≥ 30 days before the end-of-study 
visit) (yes, no) 
The secondary efficacy  variables are the following: 
1. Absolute change from  baseline in LDL -C 
2. Average percent  change from baseline in LDL -C levels to each post-baseline visit 
3. Average absolute change from baseline in LDL -C levels to each post- baseline  visit 
4. Achieving ≥ 50% reduction from baseline  in LDL -C (yes,  no) 
5. Achieving LDL -C < 100 mg/dL (yes,  no) (among the subset  of participants  with LDL -C ≥ 
100 mg/dL at baseline)  
[COMPANY_001]  Confidential  Page  50 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
6. Achieving LDL -C < 70 mg/dL (yes/no)  
7. Achieving LDL -C < 55 mg/dL (yes,  no) 
8. Percent  change from baseline  in apoB  
9. Absolute change from baseline in apoB  
10. Percent  change from baseline in non- HDL -C 
11. Absolute change from  baseline in non-HDL -C 
12. Percent  change from baseline in VLDL -C 
13. Absolute change from baseline in VLDL -C 
14. Percent  change from baseline in total cholesterol  
15. Absolute change from  baseline in total cholesterol  
16. Percent  change from baseline  in Lp(a)  
17. Absolute change from baseline in Lp(a)  
18. Percent  change from baseline in HDL -C 
19. Absolute change from baseline in HDL -C 
20. Percent  change from baseline  in triglycerides  
21. Absolute change from  baseline in triglycerides  
22. Intensity  of lipid-lowering  therapy (decrease in dose,  no change in dose, increase in dose)  
23. Proportion of days covered (total number of days on either  statin,  ezetimibe,  bempedoic 
acid or PCSK9 inhibiting monoclonal antibody therapi[INVESTIGATOR_131301]) 
 
8.3.1  Primary  efficacy assessments  
The primary  efficacy  assessments will be LDL -C and discontinuation  of statin  therapy. Samples 
for LDL -C will be collected  at screening  (Visit 1) and on visit days 2, 3, 4, 5 and 6 ( Table  8-1). 

[COMPANY_001]  Confidential  Page  51 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
8.3.2  Other  efficacy assessments  
Other  efficacy  assessments will include measurement  of Apolipoprotein B, Lp(a),  non-HDL -C, 
VLDL -C, total cholesterol, triglycerides, and HDL -C. Samples for these additional eff icacy 
biomarkers will be collected at Visits 1, 2, 3, 4, 5 and 6 ( Table 8 -1). 
 
8.3.[ADDRESS_148286] in both clinical pr actice and in trials 
evaluating the efficacy of lipid -modifying therapi[INVESTIGATOR_014] (Grundy et al 2019). Utilization of other 
therapi[INVESTIGATOR_014] (including, but not limited to, statin discontinuation, adherence  to therapi[INVESTIGATOR_131302]) are frequently used variables to evaluate the effectiveness of therapi[INVESTIGATOR_131303]. The patient -reported outcomes instruments used in this study are validated 
instruments that have been previously used in cli nical trials.  
 
8.[ADDRESS_148287] of monitoring and recording of all adverse events and serious 
adverse events, evaluation of hematology, blood chemistry and urine values, regular 
measurement of vital signs and the performance of physical examinations.  
As per Section  4.6, during a Public Health  Emergency  that limits  or prevents  on-site study  visits, 
regular phone or virtual calls should occur for safety monitoring and discussion of the participa nt´s health status until the participant can again visit the site. If a participant cannot 
visit the site to have pregnancy tests done, a home urine pregnancy test kit may be used. Participants  can perform  the urine  pregnancy test at home at the time of the scheduled  visit and 
report the result to the site, or a communication process should be established with the participant so that the site is informed of the pregnancy test results. If a visit by [CONTACT_131354], it is importa nt that participants are instructed to perform the 
urine pregnancy test first and only if the test result is negative proceed with the administration of the study treatment. 
Safety assessments are specified below with the assessment schedule detailing when  each 
assessment is to be performed.  
For details on AE collection  and reporting,  refer to AE section.  Please consult the Investigator's 
Brochure for the specific (non- routine) safety assessments.  
[COMPANY_001]  Confidential  Page  52 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
Table 8-2 Safety Assessment  
 
 
Assessment  Specification  
Physical  examination  A complete physical examination will be 
performed at Visits 1 and 6. It will include the 
examination of general  appearance,  skin, neck 
(including thyroid), eyes, ears, nose, throat, 
lungs, heart, abdomen, back, lymph nodes, 
extremities, vascular, and  
neurological  examinations.  If indicated based  on 
medical history and/or symptoms, rectal, external genitalia, breast, and pelvic exams will 
be performed. Visits 3, 4 and 5 physical exams will be a limited/focused examination.  
Information for all physical examinations must  
be included in the source documentation at the 
study site. Clinically relevant findings that are 
present prior to signing informed consent must be recorded on the appropriate eCRF that 
captures medical history. Significant findings 
made after signing informed consent  which  meet 
the definition of an Adverse Event must be 
recorded as an adverse event.  
Vital signs  Vital signs  will be assessed  at Visits  1, 2, 3, 4, [ADDRESS_148288]  0
.1 kg without  shoes,  will be measured 
at Visits 1, 2, 3, 4, 5 and 6.  
 
8.4.1  Laboratory evaluations  
Specimens will be obtained at the time points in the Assessment  Schedule  (Table  8-1). 
A central laboratory will be used for analysis of all specimens collected, with the exception of 
urine pregnancy tests and urine dipstick  tests,  which  will be done locally  (using testing  materials 
supplied by [CONTACT_131355]). Serum pregnancy tests at screening will be done by [CONTACT_19979]. Details on the collections, shipment of samples and reporting of results by [CONTACT_131356] a Laboratory Manual. 
Clinically  significant abnormalities  must be recorded as either  medical  history/current medical 
conditions or adverse events as appropriate.  
[COMPANY_001]  Confidential  Page  53 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Clinically  notable laboratory  findings  are defined in Section  16.[ADDRESS_148289] be entered on the patient's AE eCRF. If the laboratory abnormality is 
the primary reason for an unforeseen hospi[INVESTIGATOR_131304], then the procedure for rapid notification of SAEs must be follow ed. 
Likewise, if the laboratory abnormality leads to discontinuation from the study drug (temporarily or permanently), the patient must be followed until the abnormality resolves or until it is judged to be permanent. This investigation may include continued monitoring by [CONTACT_131357].  
As per Section  4.6, during a Public Health  Emergency  that limits  or prevents on- site study visits, 
if a visit by [CONTACT_6624]/home nursing staff is arranged, specimen samples should be collected 
during the visit and processed and handled in line with the study laboratory manual. 
 
[IP_ADDRESS]  Hematology  
Blood draws  for hematology will include:  
Hemoglobin, hematocrit, erythrocytes, reticulocytes, mean cell hemoglobin (MCH), mean 
corpuscular volume (MCV), mean corpuscular hemoglobin concentration (MCHC), platelet count, white blood cell count with differential. 
 
[IP_ADDRESS]  Coagulation 
Blood draws  for coagulation will include:  
Prothrombin time (PT), international normalized ratio (INR), activated partial thromboplastin (aPTT).  
 
[IP_ADDRESS]  Chemistry  
Blood draws for chemistry will be performed per the Schedule of Assessments ( Table 8 -1). 
Analysis will vary based on visit day as follows: 
• Full serum chemistry : AST , ALT, alkaline phosphatase (ALP), gamma glutamyl 
transferase (GGT), total bilirubin (TBL), direct and indirect bilirubin, creatine 
phosphokinase (CPK),  lactate dehydrogenase, bicarbonate, uric acid,  creatinine,  urea 
(BUN), estimated glomerular filtration rate (eGFR), hsCRP, sodium, potassium, magnesium, calcium, inorganic phosphate, chloride, albumin, total protein, hsCRP, glucose (fasting),  
• Limite
d serum  chemi stry: ONLY:  AST,  ALT,  ALP,  GGT,  TBL,  CPK,  creatinine,  eGFR, 
fasting glucose, hsCRP and . 

[COMPANY_001]  Confidential  Page  54 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
[IP_ADDRESS]  Urinalysis  
Urinalysis will be performed in accordance with the assessment schedule ( Table 8 -1) at the 
investigational site (a standardized dipstick test will be supplied by [CONTACT_15622]). 
Urinalysis will be performed from a sample of mid -stream urine. In case of abnormal results, 
microscopy and other assessments will be performed  at the local  laboratory  and the abnormality 
recorded as an AE.  
The following parameters will be assessed: pH, specif ic gravity, presence of blood, protein, 
glucose, ketones, nitrates, leukocyte esterase, uro- bilinogen and bilirubin. Microscopic panel 
will be only performed in the event of abnormalities (Red Blood Cells, White Blood Cells, Casts, Crystals, Bacteria, Epit helial cells).  
 
[IP_ADDRESS]  Hepatitis  markers  
Hepatitis markers will be evaluated at screening only, and will include HBV -DNA, HBsAg, 
HBsAb, HBcAb and HCV RNA -PCR. Testing will be performed in a test sequence 
recommended by [CONTACT_7698]. 
 
8.4.2  Electrocardiogram  (ECG)  
A standard [ADDRESS_148290] be recorded on the eCRF as either medical history and/or adverse events as appropriate.  
 
8.4.[ADDRESS_148291] 
(hCG) performed at visit 1 (central lab). In addition, these participants will have a urine pregnancy test conducted in the local laboratory at visits 2, 3, 4, 5 and 6. If any of these tests are positive at Visits  1 and/or 2, the participant  should not be enrolled in the trial. If a participant 
tests positive at Visits  3, [ADDRESS_148292] at home and report the result  to the site.  If a visit by [CONTACT_6624]/home  nursing staff  is arranged,  it is 
important that participants perform the urine pregnancy test first, and only if the test result is negative, proceed with the administration of the study treatment. 
 
8.4.4  Other  safety evaluations  
 
[IP_ADDRESS]  Anaphylactic reactions  
Potential anaphylactic reactions should be assessed by [CONTACT_131358] 16.4  
(Appendix 4 ). 
[COMPANY_001]  Confidential  Page  55 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
[IP_ADDRESS]  Injection site reactions  
Injection site reactions (ISRs) should be monitored at each visit from the randomization visit 
onwards and through additional contacts with the participant between visits as needed. ISRs including individual signs or symptoms at the injection site following study treatment administration should be recorded on an appropriate eCRF page. Every effort should be made to follow up with the participant until resolution of the ISR.  
 
[IP_ADDRESS]  Hyperglycemia -related events  
Laboratory results and newly added concomitant medications should be checked for potential hyperglycemia- related AEs.  
‘New onset of diabetes’  should be reported  as AE on the eCRF  in participants  with no medical 
history of diabetes when: 
  
  
• If a new concomitant medication for control of plasma glucose is added, further 
information  to assess for a diagnosis of new onset diabetes will need  to be collected  
‘Worsening of glycemic control’ should be reported as AE on the eCRF in participants with a 
medical hi
story of diabetes ( ) when:  
  
•
 New concomitant medication  or increase  in dose of current antidiabet ic therapy is initiated 
to improve the control of plasma glucose level 
 
8.4.[ADDRESS_148293] for the evaluation  of patients with atherosclerotic 
cardiovascular disease and elevated LDL -C. 
 
8.5 Additional  assessments 
No additional tests will be performed  on participants  entered  into this study.  
 
 
  

[COMPANY_001]  Confidential  Page  56 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
  
 
  
 
  
 
[IP_ADDRESS]  HealthiVibe Optional  Trial  Feedback Questionnaire  
This study includes an optional questionnaire, the “Trial Feedback Questionnaire” for 
participants to provide feedback on their clinical trial experience. Individual trial participant responses will not be reviewed by [CONTACT_431]. Responses may be used by [CONTACT_456] 
([COMPANY_001]) to understand where improvements can be made in the clinical trial process. This questionnaire does not ask questions about the trial participant's disease, symptoms, treatment effect, or adverse events, and, therefore is not considered as trial data.  
 
[ADDRESS_148294]  discontinue study  treatment  for a given  participant  if, he/she believes that 
continuation would negatively impact the participant's well -being. 

[COMPANY_001]  Confidential  Page  57 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Study treatment must be discontinued under the following  circumstances:  
• Participant/guardian  decision  
• Pregnancy  
• Use of prohibited treatment  as per recommendations in the prohibited treatment section  
• Any situation  in which  study participation  might result  in a safety  risk to the participant 
• Any severe suspected  drug related  AE at the investigator's  discretion  
If discontinua tion of study  treatment occurs,  the investigator should make a reasonable  effort to 
understand the primary  reason  for the participant’s  premature  discontinuation of study treatment 
and record this information. 
Participants who discontinue study treatment or who decide they do not wish to participate in 
the study further should NOT  be considered  withdrawn  from the study UNLESS they withdraw 
their consent (see 'Withdrawal of Informed Consent' section). Where possi ble, they should 
return for the assessments indicated in the Assessment Schedule. If they fail to return for these assessments for unknown reasons, every effort (e.g. telephone, e -mail, letter) should be 
made to contact [CONTACT_2299]/pre -designated conta ct as specified in the lost to follow -up 
section. This contact [CONTACT_6636]. Unless a participant withdraws informed consent, personal and coded data are able to be collected in accordance with the informe d consent form. 
If the participant cannot or is unwilling to attend any visit(s), the site staff should maintain regular telephone contact  [CONTACT_6635],  or with a person  pre-designated  by [CONTACT_2299]. 
This telephone contact [CONTACT_6636]. 
After study treatment discontinuation, at a minimum, in abbreviated visits, the following data 
should be collected at clinic visits or via telephone/email contact:  
• New / concomitant treatments  
• Adverse Events / Serious Adverse Events  
The investigator must also contact [CONTACT_6637]’s discontinuation from study treatment. 
 
9.1.2  Withdrawal  of informed consent  
Participants  may voluntarily  withdraw  consent to participate  in the study for any reason  at any 
time. Withdrawal of consent occurs only when a participant:  
• Does  not want  to participate  in the study  anymore,  
and 
• Does  not want  any further study related  contacts  
In this situation, the investigator should make a reasonable effort (e.g. telephone, e- mail,  letter) 
to understand the primary  reason  for the participant’s  decision to withdraw his/her consent and 
record this information.  
Study treatment must be discontinued and no further assessments conducted, and the data that woul
d have been collected at subsequent visits will be considered missing.  
[COMPANY_001]  Confidential  Page  58 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Further attempts to contact [CONTACT_131359] -up. 
All efforts should be made to complete the assessments prior to study discontinuation. A final 
evaluation at the time of the participant’s study discontinuation should be made as detailed in the assessment table.  
[COMPANY_001] will continue to retain and use all research results (data) that have already been collected for the study evaluation.  
 
9.1.[ADDRESS_148295] show "due diligence" by 
[CONTACT_6638], e.g. dates of telephone calls,  registered  letters,  etc. A participant should not be considered as lost to follow - 
up until due diligence has been completed or until the end of the study. 
 
9.1.4  Early  study termination by [CONTACT_131360]. 
Reasons for early termination:  
• Unexpected, significant,  or unacceptable safety  risk to participants  enrolled  in the study 
• Decision  based  on recommendations  from applicable board(s) after review  of safety  and 
efficacy data 
• Discontinuation of study drug development  
In taking the decision  to terminate,  [COMPANY_001] will always consider participant welfare  and safety. 
Should early  termination  be necessary,  participants must be seen as soon as possible and treated 
as a prematurely withdrawn participant. The investigator may be informed of additional 
procedures to be followed in order to ensure that adequate consideration is given to the protection of the participant’s interests. The investigator or sponsor depending on local 
regulation will be responsible for informing IRBs/IECs of the early termination of the trial.  
 
9.[ADDRESS_148296] -study treatment  
At the study completion/end of study visit, including participants who are prematurely 
withdrawn  from  the study, the referring  or primary  physician will continue  to provide ongoing 
medical care. When the participant has completed all scheduled study assessments, the investigator must call the IRT to record the participant completion in the IRT.  
Study comp letion is defined as when the last participant finishes their Study Completion Visit 
and any repeat assessments associated with this visit have been documented and followed -up 
appropriately by [CONTACT_46874], in the event of an early  study termination  decision, the date 
of that decision (e.g. Each participant will be required to complete the study in its entirety and thereafter no further study treatment will be made available to them).  
[COMPANY_001]  Confidential  Page  59 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
For study participants who have successf ully completed the study/treatment epoch, further 
guidance will be provided separately concerning continuation of treatment and access to 
investigational drug. This guidance will be provided to sites prior to the completion  visit of the 
first patient (first patient  last visit).  For study participants  who  terminate  prior to  the end  of the 
treatment epoch  or who withdraw  from  treatment,  continuing treatment should be managed  by 
[CONTACT_1755]/or referring physician.  
 
10 Safety monitoring  and reporting  
10.1 Definition  of adverse events  and reporting requirements 
10.1.1  Adverse events  
An adverse event (AE) is any untoward medical occurrence (e.g. any unfavorable and unintended sign [incl uding abnormal laboratory findings], symptom or disease) in a clinical 
investigation participant  after providing written  informed  consent  for participation  in the study. 
Therefore, an AE may or may not be temporally or causally associated with the use of a  
medicinal (investigational) product.  
The investigator has the responsibility for managing the safety of individual participant and identifying adverse events. 
[COMPANY_001]  qualified  medical  personnel will be readily  available to advise on trial related  medical 
questions or problems.  
The occurrence of adverse events must  be sought by [CONTACT_105]- directive  questioning of the participant 
at each visit during the study. Adverse events also may be detected when they are volunteered 
by [CONTACT_131361], laboratory 
test findings, or other assessments . 
Adverse events must be recorded  under the signs, symptoms, or diagnosis associated  with them, 
accompanied by [CONTACT_6644] (as far as possible) (if the event is serious refer to Section 10.1.2):  
1. The severity  grade:  
• mild: usually transient  in nature and generally  not interfering  with normal activities  
• moderate: sufficiently  discomforting  to interfere  with normal activities  
• severe:  prevents normal activities  
2. Its relationship  to the study treatment. If the event is due to lack of efficacy  or progression 
of underlying illness (i.e. progression of the study indication) the assessment of causality will usually be ‘Not suspected.’ The rationale for this guidance is that the symptoms of a lack of efficacy or progression of underlying illness are not caused by [CONTACT_6645], they happen in spi[INVESTIGATOR_6532]/or both lack of efficacy and progression of underlying disease can only be evaluated  meaningfully by [CONTACT_6646], not on a 
single participant.  
3. Its duration (start
  and end dates)  or if the event is ongoing, an outcome of not 
recovered/not resolved must be reported.  
[COMPANY_001]  Confidential  Page  60 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
4. Whether it constitutes  a SAE  (see Section  10.1.2 for definition  of SAE)  and which 
seriousness criteria have been met.  
5. Action  taken  regarding study treatment.  
All adverse events must be treated appropriately. Treatment may include one or more of the  
following:  
• Dose  not changed  
• Dose  Reduced/increased  
• Drug  interrupted/withdrawn  
6. Its outcome (i.e. recovery  status  or whether it was fatal) 
Conditions that were already present at the time of informed consent should be recorded in 
medical history of the participant.  
Adverse events (including lab abnormalities that constitute AEs) should be described using a diagnosis whenever possible, rather than individual underlying signs and symptoms. 
Adverse event monitoring should be continued for at least [ADDRESS_148297] be followed  until its resolution  or until it is judged t o 
be permanent (e.g. continuing at the end of the study), and assessment must be made at each 
visit (or more  frequently, if necessary)  of any changes in severity,  the suspected  relationship to 
the interventions required to treat it, and the outcome.  
Information about adverse drug reactions for the investigational drug can be found in the Investigator's Brochure. 
Abnormal laboratory values or test results constitute adverse events only if they fulfill at least 
one of the following criteria:  
• they induce clinical  signs  or symptoms  
• they are considered  clinically  significant 
• they require therapy  
Clinically significant abnormal laboratory values or test results must be identified through a 
review  of values outside of reference ranges/clinically  notable ranges,  significant  changes from 
baseline or the previous visit, or values which are considered to be non- typi[INVESTIGATOR_6533].  Alert  ranges for laboratory and other  test abnormalities  are included 
in Appendix 1. 
 
10.1.2  Serious adverse events  
An SAE is defined as any adverse event [appearance of (or worsening of any pre -existing)] 
undesirable sign(s),  symptom(s),  or medical  conditions(s) which  meets any one of the following 
criteria: 
• fatal 
• life-threatening  
[COMPANY_001]  Confidential  Page  61 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Life-threatening  in the context of a SAE  refers  to a reaction  in which  the participant  was at risk 
of death  at the time of the reaction; it does not refer  to a reaction  that hypothetically might have 
caused death if it were more severe (please refer to the ICH -E2D Guidelines). 
• results in persistent or significant disability/incapacity  
• constitutes a congenital anomaly/birth  defect  
• requires inpatient hospi[INVESTIGATOR_707], unless 
hospi[INVESTIGATOR_062]:  
o routine  treatment  or monitoring  of the studied  indication, not associated  with any 
deterioration in condition 
o elective  or pre-planned treatment  for a pre-existing condition that is unrelated to the 
indication under study and has not worsened since signing the informed consent 
o social  reasons and respi[INVESTIGATOR_131305]’s 
general condition 
o treatment on an emergency  outpatient basis for an event not fulfilling  any of the 
definitions of a SAE given above and not resulting in hospi[INVESTIGATOR_063] 
• is medically  significant,  e.g. defined as an event that jeopardizes the participant or may 
require medical or surgical intervention to prevent one of the outcomes listed above 
Medical  and scie ntific  judgment should be exercised  in deciding whether other situations  should 
be considered serious reactions,  such as important medical  events that might not be immediately 
life threatening or result  in death  or hospi[INVESTIGATOR_131306]. Such events should be 
considered as “medically significant.” Examples of such events are intensive treatment in an 
emergency room or at home for allergic bronchospasm, blood dyscrasias, or convulsions that 
do not result in hospi[INVESTIGATOR_131307] (please refer  to the ICH- 
E2D Guidelines ). 
All new malignant neoplasms will be assessed  as serious under “medically  significant”  if other 
seriousness criteria are not met and the malignant neoplasm  is not a disease progression of the 
study indication. 
Any suspected  transmission  via a medicinal product of an infectious  agent is also considered a 
serious adverse reaction.  
All reports of intentional misuse and abuse of the product are also considered serious adverse 
event irrespective if a clinical event has occurred.  
 
10.1.[ADDRESS_148298] be reported to [COMPANY_001].  
[COMPANY_001]  Confidential  Page  62 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
All follow- up information  for the SAE  including information  on complications, progression of 
the initial SAE and recurrent epi[INVESTIGATOR_6537] -up to the original epi[INVESTIGATOR_30755]  [ADDRESS_148299] be reported separately as a new event.  
If the SAE  is not previously  documented in the Investigator’s  Brochure or Package Insert  (new 
occurrence) and is thought to be related to the study treatment, an associate from the [COMPANY_001] 
Chief  Medical  Office  and Patient  Safety  (CMO & PS) organization may urgently require  further 
information from the investigator  for health  authority  reporti ng. [COMPANY_001] may need  to issue  an 
Investigator Notification (IN) to inform all investigators involved in any study with the same study treatment that this SAE has been reported. 
Suspected  Unexpected  Serious Adverse Reactions (S[LOCATION_003]Rs)  will be collected  and reported  to 
the competent authorities and relevant ethics committees in accordance with EU Guidance 
2011/C 172/[ADDRESS_148300] be reported to [COMPANY_001] within 24 hours of learning of its occurrence.  The pregnancy should be followed  up to determine  outcome, including spontaneous 
or voluntary termination, details of the birth, and the presence or absence of any birth defects, congenital abnormalities, or maternal and/or newborn complications. 
Pregnancy should be recorded and reported by [CONTACT_37288] (CMO&PS). Pregnancy follow -up should be recorded on the same 
form and should include an assessment of the possible relationship to the study treatment and any pregnancy outcome. Any SAE experienced during pregnancy must be reported. 
 
 
10.1.5  Reporting of study treatment  errors including misuse/abuse  
Medication errors are unintentional errors in the prescribing, dispensing, administration or monitoring of a medicine while under the control of a healthcare professional, participant or consumer (EMA definition). 
Misuse refers  to situations  where  the medi cinal  product is intentionally  and inappropriately used 
not in accordance with the protocol. Abuse  corresponds  to the persistent  or sporadic, intentional  excessive use of a medicinal  product, 
which is accompanied by [CONTACT_131362] s. 
[COMPANY_001]  Confidential  Page  63 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Study treatment errors and uses outside of  what is foreseen in the protocol will be recorded on 
the appropriate eCRF irrespective of whether or not associated with an AE/SAE and reported 
to Safety  only if associated  with  an SAE.  Misuse or abuse will be collected  and reported in  the 
safety database irrespective of it being associated with an AE/SAE within 24 hours of Investigator’s awareness.  
 
Table 10-1 Guidance  for capturing the study treatment errors  includingmisuse/abuse 
 
 
Treatment error type Document in Dosing  
eCRF  (Yes/No)  Document in AE 
eCRF  Complete  SAE form  
 
 
 
Unintentional  study 
treatment error  Yes Only if associated with 
an AE  Only if associated with 
an SAE 
 
 
Misuse/Abuse Yes Yes Yes, even if not 
associated with a SAE 
For more information on AE and SAE definition and reporting requirements, please see the respective sections.  
 
10.2 Additional  Safety Monitoring  
10.2.1  Liver  safety monitoring  
To ensure participant  safety  and enhance reliability  in determining  the hepatotoxic potential of 
an investigational drug, a standardized  process for identification  and evaluation of liver events 
consistent with normal clinical practice and monitoring. 
Please refer  to Appendix 2 (Section  16.2) for complete definitions of liver laboratory  triggers.  
Once  a participant is exposed  to study  treatment,  every  liver event defined in Table  16-3 should 
be followed  up by [CONTACT_6648], as summarized  below. 
Additional details on actions required  in case of liver events are outlined in Table  16-4 and Table  
16-5.
 Repeat liver chemistry tests (i.e., ALT, AST, TBL, PT/INR, ALP and GGT) to confirm 
elevation.  
• These liver chemistry  repeats will be performed  using the central  laboratory. If results 
will not be available from the central laboratory, then the repeats can also be 
performed  at a local  laboratory  to monitor the safety  of the participant.  If a liver event 
is subsequently reported, any local liver chemistr y tests previously conducted that are 
associated with this event should have results recorded on the appropriate CRF. 
• If the initial elevation is confirmed, close observation of the participant will be initiated,  including consideration of treatment  interruption if deemed  appropriate. 
• Discontinuation of the investigational  drug (refer  to the Discontinuation  of study 
treatment section), if appropriate  
• Hospi[INVESTIGATOR_131308]  
• Causality  assessment  of the liver event  
• Thorough follow -up of the liver event  can include based  on investigator's  discretion:  
[COMPANY_001]  Confidential  Page  64 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
- serology tests, imaging and pathology assessments, hepatologist’s consultancy; 
obtaining more  detailed  history  of symptoms  and prior or concurrent  diseases,  history 
of concomitant drug use, exclusion of underlying liver disease 
All follow -up information and procedures performed must be recorded as appropriate in the 
eCRF.  
 
10.2.2  Renal  safety monitoring  
To ensure participant  safety  and enhance reliability  in determining  the nephrotoxicity potential 
of an investigational drug, a standardized process for identification and evaluationof renal 
events consistent with normal clinical practice and monitoring. Every renal laboratory trigger or renal event as defined in Table  16-6 in  Section  16.3 ( Appendix 3) should be followed  up by 
[CONTACT_131363]  16-7 (Section  
16.3 (Appendix 3 ). 
 
10.2.3  Steering Committee  
The Steering Committee (SC) for this study will comprise of medical experts and/or clinical investigators  participating  in the trial and [COMPANY_001]  representatives from the Clinical Trial  Team. 
The SC will ensure transparent management of the study according to the protocol through recommending and approving modifications as circumstances require. The SC will provide input to the clinical  study  protocol and potential amendments to the clinical study protocol. 
Together with the Clinical Trial Team, the SC will also develop recommendations for publications of study results including authorship rules. 
 
11 Data Collection and Database management  
11.1 Data  collection  
Integrated Data  Acquisition Approach  
The study may utilize a de -identified integrated data acquisition approach entailing capture of 
data directly from available site EHR databases in addition to manual data entry by [CONTACT_20226] e 
personnel into an electronic CRF (eCRF) and integration of linked pharmacy claims data records.  
 
Direct  EHR Data  Capture  
If this approach is utilized by [CONTACT_131364], the data collection would extract source data from a participant’s  electronic medical  record and map the  data into the project  database.  When  using 
an electronic  source record  as the original point of data capture,  there  would be no additional 
manual site data entry step for the selected data. These data can be mapped directly into the project database, reducing the need for sites to perform manual data entry in the eCRFfor required routine  care study data elements that are captured  as part of the participant’s 
EHR.  If it is not possible to acquire data directly  from  the EHR,  or if source data is not integrated 
to the clinical database, data capture and data management will revert to eCRF.  
[COMPANY_001]  Confidential  Page  65 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
This study may incorporate  electronic  technology to map  EHR data into the clinical 
database consistent with Use of Electronic Health Record Data in Clinical Investigations – 
Guidance for Industry July 2018 as well as FDA  guidance regarding electronic  source and 
regulations related to the maintenance of adequate participant case histories (21 CFR 312.62 [b]). All electronic source documentation and data collected in this study will “meet the same fundamental elements of data quality (e.g. attributable,  contemporaneous, original,  and accurate) 
that are expected of “paper records” into a system that is fully validated and conforms to 21 CFR Part 11 requirements.  
Virtual / remote source  data review  will take place in order  to review  the EHR  data to confirm 
data accuracy  and to ensure all study objectives are  met when  integrated  into the clinical  study 
database.  
 
Electronic CRF Collection  
Designated  investigator staff will enter  some or all of the data required  by [CONTACT_131365]  (eCRF).  The eCRFs  have been  built using fully  validated  secure 
web-enabled  software  that conforms to [ADDRESS_148301] been  trained  in the use of the EDC system 
and data entry guidelines. Automatic validation program checks for data discrepancies in the eCRFs will be applied allowing modification and/or verification of the entered data by [CONTACT_6649].  
 
Linked Pharmacy & Medical  Claims  Data  
Partic ipants may be asked to consent to having health records made available as part of the 
collection of medical and pharmacy claims in order to assess concomitant medication and clinical  outcomes. This data would be sourced  from pharmacy  & medical  claims  databases that 
have been de -identified and tokenized to match the participant in the study. This de -identified 
data would be mapped into the project database. Logic checks to confirm accurate linkage would be performed by [CONTACT_131366].  
All data should be recorded, handled, and stored in a way that allows its accurate reporting, interpretation, and verification. All integrated data would be presented to the site in a 21 CFR Part 11 compliant system for review and clarification  of accuracy and quality. 
The investigator/designee is responsible for assuring that all data (whether entered into the eCRF or harvested from the EHR) is complete, accurate, and that entry and updates are performed  in a timely  manner. The Investigator must certify  that the data entered  are complete 
and accurate.  
After final database lock,  the investigator will receive copi[INVESTIGATOR_131309].  
 
11.2 Database  management  and quality  control  
[COMPANY_001]  personnel (or designated  CRO)  will review  the data entered  by [CONTACT_131367]. Electronic data queries stating the nature of the problem and  
[COMPANY_001]  Confidential  Page  66 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
requesting clarification will be created for discrepancies and missing values and sent to the 
investigational site via the EDC system and the Data R eview Portal. Designated investigator 
site staff are required to respond promptly  to queries and to make any necessary  changes to the 
data. 
Concomitant treatments  and prior medications entered  into the database will be coded using the 
World Health Organiza tion (WHO) Drug Reference List, which employs the Anatomical 
Therapeutic Chemical classification system. Medical history/current medical conditions and adverse events will be coded using the Medical  Dictionary  for Regulatory Activities  (MedDRA) 
terminology.  
Dates of screenings, randomizations, screen failures and study completion, as well as randomization codes and data about all study treatment (s) dispensed to the participant and all dosage changes will be tracked using an Interactive Response Technology (IRT). The system will be supplied by a vendor, who will also manage the database. The data will be sent electronically to [COMPANY_001] (or a designated CRO) at specific timelines.  
Once all the necessary actions have been completed and the database has been declared to be complete and accurate, it will be locked. Any changes to the database after that time can only 
be made after written agreement by [CONTACT_131368].  
 
11.3 Site monitoring  
Before  study  initiation,  at a site initiation  visit or at an investigator’s meeting, a [COMPANY_001] /  
representative will review the protocol and data capture requirements (i.e. direct EHR data 
capture or
 eCRFs) with the investigators and their staff. During the study, [COMPANY_001] employs 
several  methods of ensur ing protocol and GCP  compliance and the quality/integrity  of the sites’ 
data. The field monitor will conduct on -site or virtual monitoring visits to check the 
completeness of  participant records,  the accuracy  of data capture / data entry, the adherence to 
the protocol and to  Good Clinical  Practice,  the progress of enrollment,  and to ensure that study 
treatment is being stored, dispensed, and accounted for according to specifications. Video conferencing, electronic Trial Master File (eTMF) and remote source document review technologies will be utilized as needed to ensure that essential monitoring  functions are 
supported when  virtual monitoring  visits  are conducted. Key study personnel must be available 
to assist the field monitor during these visits.  
Continuous remote monitoring of each site’s data may be performed by a centralized [COMPANY_001]
/ /CRA organization. Additionally, a central analytics organization may analyze 
data & ide
ntify  risks  & trends for site operational parameters,  and provide  reports  to [COMPANY_001] 
clinical teams to assist with trial oversight.  
The inves
tigator must maintain source documents for each participant in the study, consisting 
of case and visit notes (hospi[INVESTIGATOR_131310])  containing  demographic and medical 
information, laboratory data, electrocardiograms, and the results of any other tests or assessments. All information on eCRFs must be traceable to these source documents in the participant's  file. The investigator must  also keep  the original inform ed consent  form  signed by 
[CONTACT_2299] (a signed copy is given to the participant). 

[COMPANY_001]  Confidential  Page  67 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
The investigator must give the monitor access to all relevant  source documents to confirm their 
consistency  with the data capture and/or data entry. Novar tis monitoring standards  require full 
verification  for the presence  of informed  consent, adherence to the inclusion/exclusion criteria, 
documentation of SAEs, and of data that will be used for all primary variables. Additional 
checks of the consistency of the source data with the eCRFs are performed according to the study- specific monitoring plan. No information in source documents about the identity of the 
participants will be disclosed.  
 
[ADDRESS_148302]  a two-sided  alternative 
hypothesis, employing a significance level of 0.05. 
Efficacy, safety, and other data will be summarized. For continuous variables, summary 
statistics (mean, standard deviation, median, 25th and 75th percentiles, interquartile range, minimum, and maximum) at each time point and for change from baseline to each time point will be reported by [CONTACT_1570]. For discrete variables, frequency counts and percentages at each time point will be reported by [CONTACT_1570]. 
 
12.1 Analysis  sets 
The Full Anal ysis Set (FAS)  comprises  all randomized  participants.  According to the intent- to- 
treat principle, participants will be analyzed according to the treatment group they have been assigned to during the randomization procedure. 
The Per -Protocol Set is a subset of the Full Analysis Set in which participants are not treated 
with any inclisiran  if they  are randomized  to the usual care treatment  group  or do not have any 
major protocol deviations (including deviations from inclusion/exclusion criteria) in either 
treatment group. 
The Restricted Set 1 is a subset of the Full Analysis Set, which includes only participants 
without changes in background lipid- lowering therapy.  
The Restricted Set 2 is a subset of the Full Analysis Set, which includes only participants who received three doses of inclisiran in the “inclisiran first” implementation strategy group (i.e., 
excludes patients in the “inclisiran first” implementation strategy group who missed one or 
more doses) and all participants in the usual care group (including participants who may have used commercially available inclisiran).  
The Safety Set includes all participants who received study treatment. Participants will be 
analyzed according to the study treatment received at randomization. 
[COMPANY_001]  Confidential  Page  68 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
12.2 Participant demographics and other  baseline characteristics 
Demographic and other baseline data including disease characteristics will be listed and 
summarized descriptively by [CONTACT_131369].  
Relevant  medical  histories  and curre nt medical  conditions at baseline (i.e., prior to first dose of 
study treatment) will be summarized by [CONTACT_6657], by [CONTACT_90214].  
 
12.3 Treatments 
Concomitant medications and significant non- drug therapi[INVESTIGATOR_131311] r to and after the start of 
treatment will be listed and summarized according to the Anatomical Therapeutic Chemical (ATC) classification system, by [CONTACT_1570], for the Safety Set.  
 
12.4 Analysis  supporting  primary objectives 
12.4.1  Definition  of primary  endpoint s 
The primary  efficacy  variables are the following:  
1. Percent  change from baseline in LDL -C 
2. Discontinuation of statin  therapy (i.e., no statin  use ≥ 30 days before the end-of-study 
visit) (yes, no) 
The primary  analysis time point for both primary  efficacy  variables is at Day 330. 
 
12.4.2  Statistical  model,  hypothesis,  and method of analysis 
The primary analysis of primary efficacy variable 1 to address the primary objective will be based on the following estimand: 
• Population: Defined  through appropriate inclusion/exclusion  criteria  to reflect the 
targeted population 
• Variable:  Percent  change from baseline in LDL -C [The  primary  analysis time point is 
at Day 330.] 
• Treatment:  "Inclisiran  first"  implementation  strategy  or usual  care 
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131370]. This intercurrent  event  will be ignored in the analysis,  as the design 
of the trial allows  for participants in the usual care group to potentially use inclisiran.  
2. Discontinuation  of study  treatment.  This intercurrent  event  will be ignored in the 
analysis.  
• Summary  measur
 e: Least -squares mean  difference  between  "inclisiran  first" 
implementation strategy and usual care 
The null hypothesis is that the mean percent change from baseline in LDL -C at Day 330 for 
"inclisiran first" implementation strategy and usual care groups are equal. The alternative hypothesis is that the mean percent change from baseline in LDL -C at Day 3 30 for "inclisiran 
first" implementation strategy group is not equal to that of the usual care group.  
[COMPANY_001]  Confidential  Page  69 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Primary efficacy variable 1 will be analyzed using mixed -effects model repeated measures 
(MMRM) with treatment, visit, baseline, , treatment -by- 
visit in
teraction, and baseline -by-visit interaction as explanatory variables. An unstructured 
working correlation matrix will be assumed for this model ( Diggle et a
l 2002). Least -squares 
mean of e
ach treatment group, least- squares mean treatment difference, two -sided 97.5% 
confide
nce interval for the treatment difference, and p -value based  on the fitted MMRM will 
be reported for each applicable visit (day). If the p-value based  on a two-sided  test for treatment 
effect  at Day 330 is < 0.[ADDRESS_148303] squares mean treatment  difference 
("inclisiran  first"  implementation  strategy  – usual care)  is less than 0, statistical significance  in 
favor of "inclisiran first" implementation strategy is shown. All efforts will be made  to follow 
up participants  until the end of the study. Participants  will be expected  to followthe visit schedule 
and assessments even after di scontinuation of study treatment. Data after participants 
discontinued study treatment will be used in the analysis (“retrieved dropout”). 
The primary
 analysis of primary efficacy variable 2 to address the primary objective will be 
based on the following estimand: 
• Population: Defined through appropriate inclusion/exclusion criteria to reflect the 
targeted  population and if a participant was not statin  intolerant at the beginning of the 
trial 
• Variable:  Discontinuation  of statin  therapy  (yes,  no) [The  primary  analysis time point 
is at Day 330.] 
• Treatment:  "Inclisiran  first"  implementation  strategy  or usual  care 
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131370]. This intercurrent  event  will be ignored in the analysis,  as the design 
of the trial allows  for participants in the usual care group to potentially use inclisiran.  
2. Discontinuation  of study  treatment.  This intercurrent  event  will be ignored in the 
analysis.  
• Summary  measure:  Treatment difference  ("inclisiran  first" implementation  strategy  – 
usual care) in the proportion of participants who discontinue statin therapy 
The null hypothesis is that the  difference ("inclisiran  first" implementation  strategy  – usual  care) 
in the proportion of participants  who discontinue statin  therapy  at Day [ADDRESS_148304] 0.15 (non- 
inferiority
 margin). The alternative hypothesis is that the difference ("inclisiran first" 
implementation strategy – usual care) in the proportion of participants w ho discontinue statin 
therapy at Day 330 is less than 0.15. For primary  efficacy  variable  2, a one -sided  98.75%  confi
 dence  interval  for treatment difference 
("inclisiran first" implementation strategy – usual care) in the proportion of participants who 
discontinued statin  therapy at Day 330 will be computed using  the normal approximation to the 
binomial distribution. Non- inferiority of the "inclisiran first" implementation strategy to usual 
care will be declared if the upper limit of the confidence interval does not exceed the non- 
inferiority margin of 0.15. 
The primary  ana
lysis of both prim ary efficacy  variables will be based  on the Full Analysis Set. 

[COMPANY_001]  Confidential  Page  70 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
12.4.3  Handling of intercurrent  events of primary estimand 
The remaining intercurrent events of the primary estimand for the two primary efficacy 
variables are the following: 1. Potenti al use of inclisiran  by [CONTACT_131371]. 
This intercurrent event will be ignored in the analysis, as the design of the trial allows for participants in the usual care group to potentially use inclisiran. 2. Discontinuation of study treatment.  This intercurrent event will be ignored in the analysis.  
 
12.4.[ADDRESS_148305] discontinued statin therapy. 
 
12.4.5  Sensitivity  analyses  
The sensitivity  analysis of primary  efficacy variable  1 to address the primary  objective  will be 
based on the following estimand: 
• Population: Defined  through appropriate inclusion/exclusion  criteria  to reflect the 
targeted population 
• Variable:  Percent  change from baseline in LDL -C [The  primary  analysis time point is 
at Day 330.] 
• Treatment:  "Inclisiran  first"  implementation  strategy  or usual  care 
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131370]. This intercurrent  event  will be ignored in the analysis,  as the design 
of the trial allows  for participants in the usual care group to potentially use inclisiran.  
2. Discontinuation  of study  treatment.  This intercurrent  event  will be ignored in the 
analysis.  
• Summary  measure:  Probability  of observing the same  or a more  favorable response 
with "inclisiran first" implementation strategy relative to usual care  
For the above estimand , primary  efficacy  variable  [ADDRESS_148306],  adjusting  for  
(Stokes
 et al 2012). The probability of observing the same or a more favorable response with 
"inclisiran
 first" implementation strategy relative to usual care will be estimated using 
nonparametric methods, and the associated 97.5% confi
dence interval will also be reported 
(Chen and Kianifard 2000).  
 
12.4.6  Supplementary analysis  
A supplementary analysis  of primary  efficacy  variable  1 will be based  on the following 
estimand:  

[COMPANY_001]  Confidential  Page  71 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
• Population: Defined  through appropriate inclusion/exclusion  criteria  to reflect the 
targeted population 
• Variable:  Percent  change from baseline in LDL -C [The  primary  analysis time point is 
at Day 330.] 
• Treatment:  "Inclisiran  first"  implementation  strategy  or usual  care 
• Remaining intercurrent events: 1. Potential use of inclisiran by [CONTACT_131370]. 2. Discontinuation of study treatment.  Data  after the occurrence of 
either one of the above two intercurrent events will be excluded from the analysis 
(using MMRM).  
• Summary  measure:  Least -squares mean  difference  between  "inclisiran  first" 
implementation strategy and usual care 
Subgroup analyses of the two primary  efficacy  variables will be performed  by [CONTACT_131372]- 
lowering  therapy at baseline.  Other  subgroups to be considered will be defined  in the Statistical 
Analysis Plan. 
 
12.4.7  Supportive analyses  
The primary  analysis of the two primary  efficacy  variables will be repeated  for the Per-Protocol 
Set, Restricted Set 1, and Restricted Set 2.  
 
12.5 Analysis  supporting  secondary  objectives 
12.5.1  Efficacy and/or  Pharmacodynamic endpoint(s)  
The secondary efficacy  variables are the following: 
1. Absolute change from baseline in LDL -C 
2. Average percent  change from baseline in LDL -C levels to each post-baseline visit 
3. Average absolute change from  baseline in LDL -C levels to each post-baseline visit 
4. Achieving ≥ 50% reduction from baseline in LDL -C (yes,  no) 
5. Achieving LDL -C < 100 mg/dL (yes,  no) (among the subset of participants  with LDL -C ≥ 
100 mg/dL at b aseline)  
6. Achieving LDL -C < 70 mg/dL (yes,  no) 
7. Achieving LDL -C < 55 mg/dL (yes,  no) 
8. Percent  change from baseline  in apoB  
9. Absolute change from  baseline in apoB  
10. Percent  change from baseline in non- HDL -C 
11. Absolute change from baseline in non-HDL -C 
12. Percent  change  from baseline in VLDL -C 
13. Absolute change from baseline in VLDL -C 
14. Percent  change from baseline in total cholesterol  
15. Absolute change from  baseline in total cholesterol  
16. Percent  change from baseline  in Lp(a)  
[COMPANY_001]  Confidential  Page  72 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
17. Absolute change from  baseline in Lp(a)  
18. Percent  change from baseline in HDL -C 
19. Absolute change from baseline in HDL -C 
20. Percent  change from baseline in triglycerides  
21. Absolute change from  baseline in triglycerides  
22. Intensity  of lipid-lowering  therapy (decrease in dose,  no change in dose, increase in dose)  
23. Proportion of days covered (total  number of days on either  statin,  ezetimibe,  bempedoic 
acid or PCSK9 inhibiting monoclonal antibody therapi[INVESTIGATOR_131301]) 
Analyses of secondary  eff icacy  variables 1 and 8 - 21 will be similar to the primary  analysis  of 
primary efficacy variable 1 (using MMRM, but with a two- sided 95% confiden
ce interval for 
the treatm
ent difference).  
Secondary efficacy variable 2, 3, and [ADDRESS_148307] -squares mean treatment difference, 95% 
confidence interval for the treatment difference, and p -value based on the fitted model will be 
reported.  
Secondary efficacy variables [ADDRESS_148308] -baseline visit using a logistic 
regression  model with  treatment,  baseline LDL -C, and  as 
expla
natory variables ( Stokes et al 2012).  Th
e odds ratio,  95% confidence intervals  for the odds 
ratio,  and p-value based  on the fitted  model will be reported.  Missing  data will be imputed  using 
“non-responder” (i.e., “negative” outcome) imputation. 
Secondary efficacy  varia ble [ADDRESS_148309]
anato
ry variables ( Stokes et 
al 2012). The odds ratios, 95% confidence intervals for the 
odds ratio
s, and p- values based on the fitted model will be reported. Missing data will not be 
imputed.  
Visit-to-visit LDL -C
 variability from Day 90 until Day 330 will be reported, using various 
measures of variability (standard deviation, coefficient of variation) (Bangalore et al 2015).  
Analyses of secondary  efficacy  variables  will be based  on the Full Analysis Set. 
 
12.5.2  Safety endpoints  
For all safety analyses, the Safety Set will be used. All listings and tables will be presented by 
[CONTACT_1570].  
 
Adverse events  
All information  obtained on adverse events will be displayed by [CONTACT_131373].  
The number (and percentage) of participants with treatment -emergent adverse events (events 
started after the first dose of study medication or events present prior to start of double -blind  

[COMPANY_001]  Confidential  Page  73 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
treatment but increased  in severity  based  on preferred  term) will be summarized  in the following 
ways:  
by [CONTACT_2948], primary  system  organ class and preferred  term.  
by [CONTACT_2948], primary  system  organ  class,  preferred  term and maximum severity. 
by [CONTACT_1570], Standardized MedDRA Query (SMQ) and preferred term.  
Separate summaries  will be provided for study medication  related  adverse events,  death,  serious 
adverse events, other significant adverse events leading to discontinuation. 
A participant with multiple  adverse events within  a primary  system  organ  class is only counted 
once towards the total of the primary system organ class.  
 
Vital signs  
All vital signs data will be listed by [CONTACT_1570], participant, and visit/time and if ranges 
are available, abnormalities will be flagged. Summary statistics will be provided by [CONTACT_131374]/time.  
 
Clinical  laboratory evaluations  
All laboratory data will be listed  by [CONTACT_2948],  participant,  and visit/time,  and if reference 
ranges are available, abnormalities will be flagged. Summary statistics will be provided by [CONTACT_10659]/time.  
 
12.5.3  Pharmacokinetics  
Not applicable.  
 
12.5.4  DNA  
Not applicable.  
 
12.5.5  Biomarkers  
See Section  12.5.1.  
 
12.5.6  PK/PD relationships  
Not applicable.  
 
  
 
 
  

[COMPANY_001]  Confidential  Page  75 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
15 306 354 
20 172 200 
25 112 128 
For primary efficacy variable 2, i.e., discontinuation of statin therapy (yes, no), a  for a 
non-inferior
ity test of two proportions, an allocation ratio of 1:1, and a one -sided significance 
level of 0.0125 were used in the calculation of sample size . Table 12-2 co
nsiders total sample 
sizes for 0.2
0 and 0.25 as the true  proportions of participants  who  discontinue statin  therapy in 
each treatment group, and non- inferiority margins of 0.10 and 0.15 for t
he "inclisiran first" 
implementat
ion group to be no worse  than the usual  care group  (nQuery Version  [IP_ADDRESS]). From 
Table 12-2, 
a true proportion of 0.20 for participants who discontinue statin therapy in each 
treatment gr
oup by [CONTACT_2006] 330, a non- inferiority  margin  of 0.15, and a power of 0.90 were  chosen 
to p
rovide a total sample size of 354 participants.  
 
Table 12-2    Sample  size calculations for statin therapy discontinuation  
 
Proportion in usual 
care group  Non- inferiority  margin  Power  = 0.85 Power  = 0.90 
0.20 0.10 688 796 
0.20 0.15 306 354 
0.25 0.10 806 932 
0.25 0.15 360 414 
Based on the sample size calculations in Table 12 -1 and Table 12 -2, a total sample size of  354 
together with a loss to follow -up rate of 10% at Day 330 and a statin  intolerance rate at baseline 
of 10% (i.e., a total of 20% due to loss to follow -up and statin intolerance at baseline) require 
approximately 444 participants (222 participants per treatment group) to be randomized. T his 
will also allow examination of subgroups with reasonable sample sizes. 
 
12.8.2  Secondary  endpoint(s)  
Not applicable.  
 
13 Ethical  considerations and administrative procedures  
13.1 Regulatory and ethical  compliance 
This clinical study was designed and shall be implemented,  executed  and reported  in accordance 
with the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local  regulations (including European Directive  2001/20/EC, US CFR  21), and with the ethical 
principles laid down in the Declaration of Helsinki.  
 
13.2 Responsibilities  of the investigator  and IRB/IEC  
Before  initiating  a trial, the investigator/institution  must obtain approval/favorable opi[INVESTIGATOR_131312]/Independent Ethics  Committee  (IRB/IEC) for the trial protocol, 
written  informed  consent form,  consent form  updates,  participant recruitment  procedures (e.g., 

[COMPANY_001]  Confidential  Page  76 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
advertisements)  and any other written  information  to be provided to participants.  Prior  to study 
start,  the investigator  is required to sign a protocol  signature  [CONTACT_131378]/her agreement 
to conduct the study in accordance with these documents and all of the instructions and 
procedures found in this protocol and to give access to all relevant data and records to [COMPANY_001] 
monitors,  auditors,  [COMPANY_001]  Quality  Assurance representatives,  designated agents of [COMPANY_001], 
IRBs/IECs, and regulatory authorities as required. If an inspection of the clinical site is requested  by a regulatory  authority,  the investigator must  inform [COMPANY_001] immediately  that this 
request has been made.  
 
13.[ADDRESS_148310] . In addition, after study completion (defined as last patient last visit) and 
finalization  of the study report the results  of this trial will be submitted  for publication and posted 
in a publicly accessible database of clinical  trial results,  such as the [COMPANY_001]  clinical trial results 
website and all required Health Authority websites (e.g. Clinicaltrials.gov, EudraCT etc.) 
. 
For details on the [COMPANY_001] publication policy including authorship criteria, please refer to the 
[COMPANY_001]  publication  policy t raining  materials  that were  provided to you at the trial investigator 
meetings.  
 
13.[ADDRESS_148311] Quality Management System (QMS) that includes all activities 
involved in quality assurance and quality control, to ensure compliance with written Standard 
Operating Procedures as well as applicable global/local GCP regulations and ICH Guidelines.  
Audits of investigator sites, vendors, and [COMPANY_001] systems are performed by [CONTACT_6663], independent from those  involved in conducting, monitoring  or performing  quality  control of the 
clinical trial. The clinical audit process uses a knowledge/risk based approach.  
Audits are conducted to assess GCP  compliance with global and local  regulatory  requirements, 
protocols and internal SOPs, and are performed according to written [COMPANY_001] processes. 
 
[ADDRESS_148312] any 
additional procedures for any purpose involving any investigational drugs under the protocol, other than the purpose of the study. If despi[INVESTIGATOR_131313], data, information, observation would be incidentally collec ted, the investigator shall immediately disclose it to 
[COMPANY_001] and not use it for any purpose other than the study, except for the appropriate monitoring on study participants. 
[COMPANY_001]  Confidential  Page  77 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Investigators ascertain they will apply due diligence to avoid protocol deviations. If an 
investigator feels a protocol deviation would improve the conduct of the study this must be considered  a protocol amendment, and unless such an amendment  is agreed  upon by [CONTACT_5386]/IEC and Health Authorities, where required, it cannot be implemented.  
 
14.[ADDRESS_148313] be approved by [CONTACT_5343], health authorities where required, and the IRB/IEC prior to implementation.  
Only amendments that are required for participant safety may be implemented immediately provided the health authorities are subsequently notified by [CONTACT_6670]/IEC is notified.  
Notwithstanding the need for approval of formal protocol amendments, the investigator is expected  to take any immediate  action  required for the safety  of any participant included  in this 
study, even  if this action  represents a deviation from the protocol. In such cases,  [COMPANY_001] should 
be notified of this action and the IRB/IEC at the study site should be informed according to local regulations.  
[COMPANY_001]  Confidential  Page  79 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Fitchett DH, Hegele RA, Verma  S (2015) Cardiology patient  page. Statin  intolerance. 
Circulation 131:e389-391. 
Ford  I, Norrie  J (2016) Pragmatic  Trials.  N. Engl. J. Med.  375:454- 463. 
Geisbert  TW, Hensley  LE, Kagan  E, et al (2006) Postexposure protection  of guinea pi[INVESTIGATOR_131314] a lethal ebola virus challenge is conferred by [CONTACT_76639]. J. Infect. Dis.  
193(12):1650- 7. 
Giugliano RP, Pedersen  TR, Park JG, et al (2017) Clinical efficacy  and safety  of achieving 
very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a 
prespecified secondary analysis of the FOURIER trial. Lancet 390([ZIP_CODE]):1962-1971. 
Grundy SM, Stone NJ, Bailey AL, et al (2019) 2018 
AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA  Guideline 
on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.  
Circulation  139(25):e1082- e1143.  
Horne R, Weinman  J (2002) Self-regulation and self-management  in asthma:  exploring  the 
role of illness perceptions and treatment beliefs in explaining non-adherence to preventer medication. Psychol Health 17(1):17-32. 
Khunti K, Danese MD, Kutikova L, et al (2018) Association of a Combined Measure of 
Adherence and Treatment Intensity With Cardiovascular Outcomes in Patients With Atherosclerosis or Other  Cardiovascular Risk Factors  Treated  With  Statins  and/or Ezetimibe. 
JAMA Netw Open 1(8):e185554. 
Khvorova A (2017) Oligonucleotide Therapeutics - A New Class of Cholesterol -Lowering 
Drugs. N. Engl. J. Med. 376(1):4-7. Koren MJ, Hunninghake DB, (2004) Clinical outcomes in managed- care patients with 
coronary heart  disease treated  aggressively in lipid-lowering  disease  management  clinics:  the 
alliance study. J. Am. Coll. Cardiol 44(9):1772-1779. 
Landmesser U, Haghikia A, L eiter LA, et al (2020) Effect of inclisiran, the siRNA against 
PCSK9,  on platelets,  immune  cells and immunological biomarkers  - a pre-specified  analysis 
from ORION -1. Cardiovasc. Res. 117(1):284-291. 
Lowenstern  A, Li S, Navar AM, et al (2018) Does clinicia n-reported lipid guideline  adoption 
translate  to guideline- adherent  care? An  evaluation of the Patient  and Provider Assessment  of 
Lipid Management (PALM) registry. Am. Heart J. 200:118-124. 
Mann  DM, Woodward M, Muntner P, et al (2010) Predictors  of nonadherence to statins:  a 
systematic review and meta-analysis. Ann Pharmacother. 44(9):1410-1421. Morrissey  DV,  Blanchard  K, Shaw  L, et al (2005) Activity  of stabilized  short interfering  RNA 
in a mouse model of hepatitis B virus replication. Hepatology 41(6):1349-1356. 
[COMPANY_001]  Pharmaceuticals Corp
 oration  (2020), Inclisiran  (KJX839) Investigator's Brochure, 
15th edition. 
[COMPANY_001]  Confidential  Page  80 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Poluzzi E, Strahinja  P, Lanzoni M, et al (2008) Adherence to statin  therapy  and patients' 
cardiovascular risk: a pharmacoepi[INVESTIGATOR_76602]. Eur. J. Clin. Pharmacol. 
64(4):425- 432. 
Raal FJ, Kallend  D, Ray KK, et al (2020) Inclisiran  for the Treatment  of Heterozygous 
Familial Hypercholesterolemia. N. Engl. J. Med. 382:1520-1530. 
Ray KK, Landmesser  U, Leiter  LA, et al (2017) Inclisiran  in Patients  at High  Cardiovascular 
Risk with Elevated LDL Cholesterol. N. Engl. J. Med. 376(15):1430-1440. Ray KK, Wright R S, Kallend  D, et al (2020) Two Phase 3 Trials  of Inclisiran  in Patients  with 
Elevated LDL Cholesterol. N. Engl. J. Med. 382:1507-1519. 
Roth  GA, Johnson C, Abajobir A, et al (2017) Global, Regional, and National  Burden of 
Cardiovascular Diseases for 10 Causes, 1990 to 2015. J. Am. Coll. Cardiol. 70(1):1- 25. 
Rymer  JA, Mues KE, Monda KL, et al (2020) Use of Low-Density  Lipoprotein -Lowering 
Therapi[INVESTIGATOR_131315]9 Inhibitor Initiation 9(9):e014347.  
Sampson HA, Muñoz-Furlong A, Bock  SA, et al (2005) Symposium on the definition  and 
management of anaphylaxis: summary report. J Allergy Clin Immunol; 115(3): 584- 91. 
Sampson HA, Muñoz-Furlong A, Campbell RL, et al (2006) Second symposium on the 
definition and management o f anaphylaxis: summary report --Second National Institute of 
Allergy  and Infectious  Disease/Food  Allergy  and Anaphylaxis Network  symposium. J Allergy 
Clin Immunol;117(2): 391 -7. 
Soutschek J, Akinc A, Bramlage  B, et al (2004) Therapeutic silencing of an endogenous gene 
by [CONTACT_76640]. Nature 432(7014):173- 8. 
Stokes ME, Davis  CS, Koch  GG (2012) Categorical  data analysis using the SAS system.  3rd 
ed; Cary, NC: SAS Institute, Inc.  
Tabernero J, Shapi[INVESTIGATOR_76604], LoRusso PM, et al (2013) First- in-humans trial of an RNA 
interference  therapeutic targeting  VEGF  and KSP in cancer  patients  with liver involvement. 
Cancer Discov 3(4):406-17. 
Thorpe KE, Zwarenstein M, Oxman AD, et al (2009) A pragmatic-explanatory continuum 
indicator summary  (PRECIS):  a tool to help trial designers.  J Clin Epi[INVESTIGATOR_5541] 62(5):464-75. 
Virani SS, Alonso A, B
 enjamin  EJ, et al (2020) Heart  Disease and Stroke Statistics-2020 
Update: A Report From  the American  Heart  Association.  Circulation  141(9): e139- e596.  
Wong ND, Young D, Zhao Y, et al Prevalence of the American College of Cardiology/American  Heart  Association  statin  eligibility  groups, statin  use, and low-density 
lipoprotein cholesterol control in US adults using the National Health and Nutrition Examination Survey 2011-2012. J Clin Lipi[INVESTIGATOR_37487] 10(5):1109- 18. 
Zimmermann  TS, Lee AC, Akinc A, et al (2006) RNAi -mediated  gene silencing in non- 
human primates. N ature 441(7089):111-4. 
[COMPANY_001]  Confidential  Page  81 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
van der Velden JM, Verkooijen HM, Young- Afat DA, et al (2017) The cohort multiple 
randomized controlled  trial design: a valid  and efficient alternative  to pragmatic  trials?  Int J 
Epi[INVESTIGATOR_5541] 46(1): 96 -102. 
[COMPANY_001]  Confidential  Page  82 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
16 Appendices 
16.1 Appendix 1: Clinically  notable laboratory values and vital signs  
Vital signs range deviations are defined in Table  16-1 : 
 
Table  16-1 Clinically notable vital signs  
 
Vital  sign Notable  abnormalities  
Pulse  (beats/min)  either  ≥120 + increase ≥25* 
or > 130 
either  ≤50 + decrease  ≥30* or 
< 40 
BP (mmHg)  systolic either  ≥180  + increase≥30*  or > 
200either ≤90 + decrease≥30* 
or < 75  
diastolic  either  ≥105  + increase≥20*  or > 
115either ≤50 + decrease≥20* 
or < 40  
* Refers  to post-BL value as compared to BL value 
Notable laboratory  values  are defined in Table  16-2 : 
 
Table  16-2 Clinically notable laboratory abnormalities for selected tests  
 
Parameters  Criteria  
Hematology  
Hemoglobin  ≤ 10 g/dL 
Hematocrit  ≤ 0.8 × LLN 
WBC  (total)  ≤ 2.8 ×103 / μL, ≥ 16 ×103 / μL 
Platelet  count  ≤ 75 ×103 / μL, ≥ 700 ×103 / μL 
  
Clinical  chemistry  
Creatinine  > 2 mg/dL  
CPK > 1 and ≤ 3 × ULN 
CPK > 3 and ≤ 5 × ULN 
CPK > 5 and ≤ 10 × ULN 
CPK > 10 × ULN 
ALT > 1 and ≤ 3 × ULN 
ALT > 3 and ≤ 5 × ULN 
ALT > 5 × ULN 
AST > 1 and ≤ 3 × ULN 
AST > 3 and ≤ 5 × ULN 
AST > 5 × ULN 
Total  bilirubin  > 2 × ULN 
ALP > 2 × ULN 

[COMPANY_001]  Confidential  Page  83 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
16.2 Appendix 2: Liver  event  and laboratory  trigger  definitions  & 
follow -up requirements  
Table  16-3 Liver  event and laboratory trigger  definitions  
 
 Definition/  threshold  
Liver  laboratory  triggers  • ALT or AST > 5 × ULN 
If ALT,  AST and total bilirubin  normal  at 
baseline:  • ALP > 2 × ULN (in the absence of known 
bone pathology)  
 • Total  bilirubin  > 3 × ULN (in the absence of 
known Gilbert syndrome)  
 • ALT or AST > 3 × ULN and INR > 1.5 
 • Potential  Hy’s Law cases (defined as ALT  or 
AST > 3 × ULN and Total  bilirubin  > 2 × ULN 
[mainly conjugated fraction] without notable 
increase in ALP to > 2 × ULN)  
 • Any clinical  event  of jaundice (or equivalent 
term)  
 • ALT or AST > 3 × ULN accompanied by 
(general)  malaise,  fatigue,  abdominal  pain, 
nausea, or vomiting, or rash with 
eosinophilia  
 • Any adverse  event  potentially  indicative of a 
liver toxicity*  
If ALT or AST abnormal  at baseline:  • ALT or AST > 2x baseline  or > 300 U/L 
(whichever occurs first)  
*These events cover the following: hepatic failure, fibrosis and cirrhosis, and other liver damage- 
related conditions;  non-infectious  hepatitis;  benign,  malignant  and unspecified liver neoplasms  ULN: 
upper limit of normal  
 
Table 16-[ADDRESS_148314] increase  without  bilirubin  increase:   
If normal at baseline:  
ALT or AST > [ADDRESS_148315] Normal  
For patients with 
Gilbert’s  syndrome:  No 
change in baseline TBL  
 
 
 
 
None • No change to 
study  treatment  
• Measure ALT, 
AST,  ALP,  GGT, 
TBL,  direct  and 
indirect  
bilirubin, PT/INR, 
albumin,  CPK,  and 
GLDH in 48 -72 
hours.  
• Follow -up for 
symptoms. If elevated  at 
baseline:  
ALT or AST > 2 x 
baseline 
or > 300 U/L 
(whichever  occurs 
ﬁrst) 
[COMPANY_001]  Confidential  Page  84 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
ALT or AST TBL Liver  Symptoms  Action  
If normal  at baseline:  Normal   
 
 
 
 
None  
 
 
 
 
• Interrupt study 
drug  
1. Measure  ALT, 
AST,  ALP, 
GGT,  TBL, 
direct and 
indirect bilirubin,  PT/IN 
R, albumin, CPK, and GLDH in 48 - 
72 hours.  
• Follow -up for 
symptoms. 
• Initiate close 
monitoring  and 
workup for 
competing 
etiologies.  
• Study  drug can be 
restarted only if another etiology  is 
identiﬁed and liver 
enzymes  return to 
baseline.  ALT or AST > [ADDRESS_148316] 
for more  than two 
weeks  For patients with 
Gilbert’s  syndrome:  No 
change in baseline 
TBL If elevated  at 
baseline:  
ALT or AST > 3 x 
baseline  
or > 300 U/L 
(whichever occurs  
ﬁrst) for more  than two 
weeks   
If normal  at baseline:  Normal  None ALT or AST > [ADDRESS_148317] increase  with bilirubin  increase:  
If normal at baseline:  
ALT or AST > [ADDRESS_148318] TBL > [ADDRESS_148319] (or 
INR > 1.5)   
 
 
 
None If elevated  at 
baseline:  
ALT or AST > 2 x 
baseline  For patients  with 
Gilbert’s  syndrome: 
Doubling of direct 
bilirubin  
or > 300 U/L 
(whichever  occurs  
ﬁrst)  
If normal  at baseline:   
 
 
 
Normal  or elevated  
 
 
Severe fatigue, nausea,  vomiting,  right 
upper quadrant pain  ALT or AST > [ADDRESS_148320] 
If elevated  at 
baseline:  
ALT or AST > 2 x 
baseline 
or > 300 U/L 
(whichever  occurs 
ﬁrst) 
 
Table  16-5 Follow  up requirements for liver laboratory triggers  
 
Criteria  Actions  required  Follow -up monitoring  
Total  Bilirubin  (isolated)    
>1.5 – 3.[ADDRESS_148321] • Maintain  treatment  
• Repeat  LFTs within  48-72 
hours  Monitor LFTs weekly until resolution
a to ≤ Grade 1 or to 
baseline 
> 3 - 10 × ULN (in the absence 
of known Gilbert syndrome)  • Interrupt  treatment  
• Repeat  LFT within  48-72 
hours  Monitor LFTs weekly until 
resolutiona to ≤ Grade 1 or to 
baseline (ALT, AST, total  
[COMPANY_001]  Confidential  Page  85 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Criteria  Actions  required  Follow -up monitoring  
 • Hospi[INVESTIGATOR_131316]  
• Establish  causality  
• Record the AE and 
contributing factors (e.g. 
conmeds,  med hx, lab) in 
the appropriate eCRF  bilirubin,  Alb, PT/INR,  ALP and 
GGT)  
Test for hemolysis (e.g. 
reticulocytes,  haptoglobin, 
unconjugated [indirect] bilirubin)  
> [ADDRESS_148322] • Discontinue the study 
treatment  immediately  
• Hospi[INVESTIGATOR_131317]  
• Establish  causality  
• Record the AE and 
contributing factors(e.g. 
conmeds,  med hx, lab) in 
the appropriate eCRF  ALT,  AST,  total bilirubin,  Alb, 
PT/INR, ALP and GGT until 
resolutionc (frequency at 
investigator discretion)  
Any AE potentially  indicative of 
a liver toxicity*  • Consider  study  treatment 
interruption or 
discontinuation 
• Hospi[INVESTIGATOR_131318]  
• Establish  causality  
• Record the AE and 
contributing factors(e.g., 
conmeds,  med hx, lab) in 
the appropriate eCRF  Investigator  discretion  
aResolution is defined as an outcome of one of the following:  (1) return to baseline values,  (2) stable 
values at three subsequent monitoring visits at least 2 weeks apart, (3) remain at elevated level  
after a maximum of 6 months, (4) liver transplantation, and (5) death.  
Based on investigator’s discretion investigation(s) for contributing factors for the liver event 
can include: Serology tests, imaging and pathology assessments, hepatologist’s consultancy; obtaining more detailed history of symptoms and prior or concurrent diseases, history of concomitant drug use, exclusion of underlying liver disease.  
[COMPANY_001]  Confidential  Page  86 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
16.3 Appendix 3: Specific Renal  Alert  Criteria  and Actions and Event 
Follow -up 
Table  16-6 Specific Renal Alert  Criteria  and Actions  
 
Renal  event  Actions  
Confirmed serum  creatinine increase (sCR)  25 – 
49% Consider  causes  and possible interventions  
Follow  up within  2-5 days 
Serum  creatinine increase ≥ 50% + + OR if <18 
years old, eGFR ≤ 35 mL/min/1.73 m2 + Consider  causes  and possible interventions  
Repeat  assessment  within  24-48h if possible 
Consider  drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected 
Consider  participant  hospi[INVESTIGATOR_131319] ≥ 3+ 
OR 
Protein -creatinine ratio (PCR) ≥ 1g/g Cr (or 
mg/mmol equivalent as converted by [CONTACT_131375])  Consider causes and possible interventions 
Assess serum  albumin  & serum  total protein 
Repeat assessment to confirm  
Consider  drug interruption or discontinuation 
unless other causes are diagnosed and 
corrected  
New onset  hematuria ≥ 3+ on urine  dipstick  Repeat  assessment  to confirm  
Distinguish  hemoglobinuria from hematuria 
Urine sediment microscopy  
Assess sCr 
Exclude  infection,  trauma,  bleeding from the 
distal urinary tract/bladder, menstruation  
Consider  bleeding  disorder  
+ Corresponds  to KDIGO  (Kidney  Disease:  Improving  Global  Outcomes)  criteria  for Acute  Kidney 
Injury  
Additional specialized assessments are available to assess renal function or renal pathology. 
(Note: In exceptional cases, when a nephrologist considers a renal biopsy, it is recommended 
to make slide  specimen  available for evaluation by [CONTACT_131376] -wide 
patterns of nephrotoxicity.) 
Whenever  a renal  event  is identified, a detailed  patient history  and examination  are indicated  to 
identify  and potentially eliminate  risk factors  that may have initiated  or contributed  to the event: 
• Blood pressure assessment  (after  5-minute rest, with an appropriate cuff size) 
• Signs and symptoms  like fever,  headache,  shortness of breath, back  or abdominal pain, 
dysuria or hematuria, dependent or periorbital edema  
• Changes in blood pressure,  body weight, fluid  intake,  voiding pattern, or urine  output  
• Concomitant events or procedures such as trauma,  surgical  procedures, cardiac  or hepatic 
failure, contrast media or other known nephrotoxin administration, or other diseases or 
causes, e.g., dehydration due to delirium, tumor lysis 
[COMPANY_001]  Confidential  Page  87 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
Table  16-[ADDRESS_148323]  in appropriate  eCRF(s):  
Urine dipstick and sediment microscopy evidence of DIN: crystals, red blood cells 
(dysmorphic/glomerular vs. non-dysmorphic/non- glomerular),  white  blood cells,  tubular  epi[INVESTIGATOR_131320],  BUN,  electrolytes  (sodium,  potassium,  phosphate,  calcium),  bicarbonate and uric 
acid 
Urine  output  
Review  and record  possible contributing  factors  to the renal  event  (co-medications,  other  co-morbid 
conditions) and additional diagnostic procedures (MRI etc.) in the appropriate eCRF(s)  
Monitor  participant  regularly  (frequency  at investigator’s  discretion)  until – 
• Event  resolution:  (sCr within  10% of baseline or PCR  < 1 g/g Cr, or ACR  <300  mg/g  Cr) 
or 
• Event  stabilization:  sCr level with ±10%  variability  over last 6 months  or protein- creatinine ratio 
stabilization at a new level with ±50% variability over last 6 months.  
• Analysis  of urine markers  in samples  collected over the course  of the DIN event  
ACR  (Albumin -to-creatinine ratio),  DIN (Drug -Induced Nephrotoxicity),  PCR  (Protein -creatinine  ratio), 
MRI (Magnetic Resonance Imaging), sCR (serum creatinine)  
[COMPANY_001]  Confidential  Page  88 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
16.4 Appendix 4: Sampson  Criteria  for Diagnosing  Anaphylaxis 
Anaphylaxis is highly likely  when  any one of the following  three  criteria  is fulfilled: 
1. Acute  onset of an illness (minutes  to several  hours) with involvement of the skin, mucosal 
tissue, or both (e.g., generalized hives, pruritus or flushing, swollen lips-tongue-uvula) 
AND AT LEAST ONE  OF THE  FOLLOWING:  
a. Respi[INVESTIGATOR_11310]  (e.g., dyspnea, wheeze-bronchospasm, stridor,  reduced peak 
expi[INVESTIGATOR_10229] [PEF], hypoxemia) 
b. Reduced blood pressure or associated  symptoms  of end- organ dysfunction (e.g., hypotonia 
[collapse], syncope, incontinence) 
2. Two or more of the following that occur rapi[INVESTIGATOR_17176] a likely allergen for that 
patient (minutes to several hours):  
a. Involvement of the skin-mucosal tissue  (e.g., generalized  hives,  itch-flush, swollen  lips- 
tongue -uvula)  
b. Respi[INVESTIGATOR_11310]  (e.g., dyspnea, wheeze,  bronchospasm, stridor,  reduced PEF, 
hypoxemia  
c. Reduced  BP or associated  symptoms (e.g., hypotonia [collapse],  syncope, incontinence)  
d. Persistent  gastrointestinal symptoms  (e.g., painful abdominal cramps,  vomiting)  
3. Reduced  blood  pressure after exposure to a known allergen  for that patient (minutes  to several 
hours):  
a. Infants and children:  low systolic blood pressure  (age specific)  or > 30% decrease in 
systolic blood pressure* 
b. Adults: systolic blood pressure <90 mmHg  or >30% decrease from that person’s baseline 
*Low systolic blood pressure for children is age specific and defined as: <70 mmHg  for age 
1 month to 1 year;  <70 mmHg  + [2 x age] for age 1 to years;  <90 mmHg  for age 11 to 17 years 
Source: ( Sampson et al 2005)  and ( Sampson et al 2006) 
[COMPANY_001]  Confidential  Page  89 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 

[COMPANY_001]  Confidential  Page  90 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 
 

[COMPANY_001]  Confidential  Page  91 of 91 
Protocol  No. CKJX839A1US02  Amended  Clinical  Trial Protocol  (Version  No. 02)  
 
 
 
 
 
 
 
 
